QT Imaging Delivers Strong Second Quarter Growth While Building the Foundation for Commercial Scale

QT Imaging Delivers Strong Second Quarter Growth While Building the Foundation for Commercial Scale

Second-quarter revenue reached $7.4 million; first-half revenue increased 116% to $14.0 million, with 28 scanners shipped

Strengthened capital position through a $10.0 million public offering and expanded direct U.S. commercial capabilities to accelerate adoption

Reaffirms full-year 2026 revenue guidance of approximately $39 million

Conference Call begins at 4:30 p.m. Eastern Time today

NOVATO, Calif.–(BUSINESS WIRE)–
QT Imaging Holding, Inc. (Nasdaq: QTI) (“QT Imaging” or the “Company”), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today reported financial results for the three and six months ended June 30, 2026, and provided a business update.

“Our second quarter results demonstrate continued execution and the growing commercial momentum of QT Imaging. Revenue more than doubled year-over-year to $7.4 million, and we shipped fifteen Breast Acoustic CT scanners during the quarter, compared with eight in the prior-year period,” said Dr. Raluca Dinu, Chief Executive Officer of QT Imaging. “We also took important steps to support continued growth, completing a $10 million public offering, expanding our direct U.S. sales organization, and securing regulatory authorization in Israel and Saudi Arabia. At the same time, we generated new evidence demonstrating less than 1% variability in Speed of Sound measurements across our scanners, successfully completed our first routine FDA inspection with zero Form 483 observations, and expanded manufacturing capacity through our new 22,000-square-foot facility. These are tangible steps toward scaling Breast Acoustic CT commercially while building the clinical, regulatory and operational foundation for broader adoption.”

“With more than 12,000 women already imaged using our technology, we are building more than an innovative medical imaging system; we are building a quantitative breast imaging platform that integrates advanced hardware, software, cloud infrastructure and, over time, AI-enabled clinical applications,” added Dr. Dinu. “At the same time, we continue to evolve our commercial strategy by complementing our established distribution partnerships with expanded direct commercial, and business development capabilities to accelerate customer engagement and broaden adoption. While geopolitical developments have impacted commercial activities in parts of the Gulf region, we are beginning to see encouraging signs of renewed customer engagement.”

Second Quarter and Recent Business Highlights

  • Continued commercial execution: QT Imaging shipped 15 Breast Acoustic CT scanners during the second quarter of 2026 and 28 scanners during the first six months of the year. The revenue for the second quarter of 2026 was $7.4 million. The Company continues to pursue commercial opportunities through a combination of established distribution partners and its expanding internal commercial and business development capabilities.
  • Strengthened capital position: During the second quarter, QT Imaging completed an underwritten public offering that generated approximately $10.0 million in gross proceeds. The Company also extended the maturity of its senior secured term loan by two years, from March 31, 2027, to March 31, 2029.
  • Built a scalable U.S. commercial organization: Under the leadership of our Chief Commercial Officer Satrajit Misra, a seasoned medical imaging executive with three decades of industry experience, QT Imaging expanded its direct commercial organization with the appointments of Jason Dyer as Vice President, Regional Sales East, and Dave Reinhart as Vice President, Regional Sales West. Together, this team strengthens the Company’s ability to directly engage breast imaging centers, clinicians and enterprise health systems, deepen strategic customer relationships and complement its established distribution partnerships, creating a scalable commercial model designed to accelerate adoption, grow the installed base and support long-term revenue growth and margin expansion.
  • Expanded global regulatory foundation for Breast Acoustic CT scanners: During the quarter, the Company received AMAR authorization from Israel’s Ministry of Health and Food and Drug Administration (“FDA”) regulatory clearance in Saudi Arabia. QT Imaging continues to pursue additional regulatory authorizations in the Gulf region and Europe.
  • Successfully completed the Company’s first routine FDA inspection: The inspection concluded with zero Form 483 observations, reflecting the strength of the Company’s Quality Management System and its focus on quality, compliance and manufacturing readiness.
  • Generated additional scientific evidence: A multi-site repeatability and reproducibility study demonstrated less than 1% variability in Speed of Sound measurements across Breast Acoustic CT scanners. The results support the potential use of objective and reproducible quantitative imaging biomarkers in longitudinal breast health assessment and treatment monitoring. These results reflect testing performed under the study conditions and do not represent a new FDA-cleared indication.
  • Continued advancing the QTI technology platform: Development activities included enhancements to image reconstruction, quantitative imaging algorithms, clinical workflow, and the QTI Precision Pathway™ cloud platform. The Company also continued its collaboration with Olea Medical to productize its multimodality image viewer, physician workflow and quantitative image analysis.
  • Strengthened clinical and scientific leadership: Appointed Dr. Julia Albright as Chief Science Officer, effective July 27, 2026, and welcomed nationally recognized breast surgical oncologist Dr. Barry Roseman as Senior Medical Advisor. Dr. Albright brings more than three decades of leadership in medical imaging innovation, quantitative imaging and artificial intelligence, with a proven track record of translating advanced technologies into clinically impactful products. Dr. Roseman brings more than 30 years of experience in breast cancer diagnosis, treatment and multidisciplinary patient care, providing deep clinical expertise to support physician engagement, clinical implementation, and broader adoption of our technology.
  • Advanced clinical expansion in Israel: Following our recent AMAR authorization from Israel’s Ministry of Health, the first Breast Acoustic CT scanner in Israel is planned for placement at Rambam Health Care Campus, one of the country’s leading academic medical centers. The scanner will support a planned clinical study evaluating Breast Acoustic CT imaging modality in women with hereditary risk for breast cancer, expanding the Company’s clinical evidence-generation efforts in an important high-risk population.
  • Expanded manufacturing capacity while improving operating efficiency: Continued investing in manufacturing excellence and supply chain readiness while relocating to a new 22,000-square-foot headquarters and manufacturing facility, located in Petaluma, CA. The expanded facility provides more than 2.5x the operational space of the current location while reducing lease cost per square foot by approximately 55%, enhancing the Company’s ability to scale production efficiently.
  • Increased visibility within the investment community: QT Imaging was added to the Russell Microcap® Index as part of the 2026 semi-annual Russell index reconstitution and following its return to the Nasdaq Capital Market in January.
  • Pursued grassroots initiatives focused on breast health: Dr. Dinu participated in two prestigious events hosted by The Shift, including its inaugural Shiftmakers Gala celebrating women driving change held at Harvard University and featuring actress and breast cancer survivor Olivia Munn, and presenting the Shiftmaker Award to tennis legend and two-time cancer survivor Martina Navratilova at the Sports Shiftmaker Awards ceremony during Wimbledon week in London.

Second Quarter 2026 Financial Results

Revenue for the second quarter of 2026 was $7.4 million, an increase of 103% compared with $3.7 million for the second quarter of 2025. The increase was primarily attributable to the shipment of fifteen Breast Acoustic CT scanners in the 2026 quarter, compared with eight in the prior-year quarter.

Gross margin was 41% for the second quarter of 2026, compared with 50% for the second quarter of 2025. The gross margin for the second quarter of 2026 was in line with our projections for sales in the USA. The higher prior-year gross margin reflected a lower weighted average cost of inventory sold.

Total operating expenses were $4.9 million for the second quarter of 2026, compared with $2.9 million for the second quarter of 2025. The increase was primarily attributable to employee compensation and benefits, professional service costs, and marketing expenses.

Operating loss for the second quarter of 2026 was $1.9 million, compared with an operating loss of $1.0 million, for the second quarter of 2025 and $2.3 million for the first quarter of 2026.

Total interest and other expense, net, was $9.2 million during the second quarter of 2026, compared with $3.0 million in the prior-year quarter. The increase was due primarily to an $8.3 million non-cash loss on debt extinguishment related to the Lynrock Lake term loan modification.

Net loss for the second quarter of 2026 was $11.1 million, or $0.75 per share, compared with a net loss of $4.0 million, or $0.42 per share, for the second quarter of 2025. Prior-period share and per-share amounts have been adjusted to reflect the Company’s 3:1 reverse stock split completed in October 2025.

Non-GAAP adjusted EBITDA, which excludes interest, taxes, depreciation and amortization, other income or expense, changes in the fair value of financial liabilities, and stock-based compensation, was negative $1.2 million, or $0.08 per share, for the second quarter of 2026, compared with negative $0.8 million, or $0.08 per share, for the second quarter of 2025.

Net cash used in operating activities during the second quarter of 2026 was $4.8 million, compared with $1.4 million during the second quarter of 2025.

As of June 30, 2026, the Company had cash and restricted cash of $11.0 million, compared with $10.5 million as of December 31, 2025. As of August 7, 2026, the Company had cash and restricted cash of $14.2 million.

2026 Revenue Outlook

The Company affirms its 2026 revenue guidance of approximately $39 million. This outlook reflects minimum order quantities under its distribution agreements, as well as expected contributions from the Company’s direct sales efforts.

Conference Call and Webcast

QT Imaging management will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update. Participants are encouraged to pre-register here. Callers who are unable to pre-register can access the call by dialing 866-777-2509 (U.S.) or 412-317-5413 (international). A live and archived webcast of the call will be available at this link and on the IR Calendar section of the QT Imaging website.

Non-GAAP Financial Measures

Some of the financial information and data contained in this press release, such as EBITDA and Adjusted EBITDA, have not been prepared in accordance with GAAP. To supplement our unaudited condensed consolidated financial statements, which are prepared and presented in accordance with GAAP in our press release, we also report certain non-GAAP financial measures. A “non-GAAP financial measure” refers to a numerical measure of a company’s historical or future financial performance, financial position or cash flows that excludes (or includes) amounts that are included in (or excluded from) the most directly comparable measure calculated and presented in accordance with GAAP in such company’s financial statements. Non-GAAP financial measures should not be considered in isolation or as a substitute for the relevant GAAP measures and should be read in conjunction with information presented on a GAAP basis. Because not all companies use identical calculations, our presentation of non-GAAP measures may not be comparable to other similarly titled measures of other companies.

The presentation of these financial measures is not intended to be considered in isolation or as a substitute for, or superior to, financial information prepared and presented in accordance with GAAP and should not be considered measures of QT Imaging’s liquidity. Investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool. In particular, many of the adjustments to our GAAP financial measures reflect the exclusion of certain items, as defined in our non-GAAP definitions below, which are recurring and will be reflected in our financial results for the foreseeable future. In addition, these measures may be different from non-GAAP financial measures used by other companies, even where similarly titled, limiting their usefulness for comparison purposes and therefore should not be used to compare QT Imaging’s performance to that of other companies. We endeavor to compensate for the limitation of the non-GAAP financial measures presented by also providing the most directly comparable GAAP measures and descriptions of the reconciling items and adjustments to derive the non-GAAP financial measures.

We believe these non-GAAP financial measures provide investors and analysts with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance, and allow for greater transparency with respect to key measures used by management to operate and analyze our business over different periods of time.

EBITDA is defined as loss before interest expense, income tax expense, depreciation and amortization. Adjusted EBITDA is defined as EBITDA further adjusted for other expense (income), change in fair value of the warrant, derivative, and earnout liabilities, loss on issuance of debt, loss on debt extinguishment and modification, and stock-based compensation. Similar excluded expenses may be incurred in future periods when calculating these measures. QT Imaging believes these non-GAAP measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to the Company’s financial condition and results of operations. QT Imaging believes that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating projected operating results and trends and in comparing QT Imaging’s financial measures with other similar companies, many of which present similar non-GAAP financial measures to investors.

Management does not consider these non-GAAP measures in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of these non-GAAP financial measures is that they exclude significant expenses and income that are required by GAAP to be recorded in the Company’s consolidated financial statements. In addition, they are subject to inherent limitations as they reflect the exercise of judgment by management about which expense and income items are excluded or included in determining these non-GAAP financial measures.

Management uses EBITDA and Adjusted EBITDA as a non-GAAP performance measure that is defined in the accompanying tables and is reconciled to net loss, the most directly comparable GAAP measure, in the tables below.

We present reconciliations of these non-GAAP financial measures to the most directly comparable GAAP measures in the tables below.

About QT Imaging

QT Imaging Holdings, Inc. (Nasdaq: QTI) is a medical device company engaged in the research, development, and commercialization of innovative imaging systems that use low-frequency sound waves. QT Imaging Holdings, Inc. strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient’s experience. For more information on QT Imaging Holdings, Inc., please visit the Company’s website at www.qtimaging.com and follow us on LinkedIn.

Breast Acoustic CT™ is a trademark of an affiliate of QT Imaging Holdings, Inc.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act of 1934, as amended. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding QT Imaging’s quality and regulatory compliance and its ability to scale manufacturing, expand commercialization globally, and support a growing customer base, plans for QT Imaging, new product development and introduction, product sales growth and projected revenues, QT Imaging’s industry, future events, and other statements that are not historical facts. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. These statements are based on various assumptions, whether or not identified herein, and on the current expectations of QT Imaging’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by you or any other investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond our control. These forward-looking statements are subject to a number of risks and uncertainties, including those relating to: the ability of the Company to sell and deploy the QT Imaging Breast Acoustic CT™ Scanner; the ability to extend product offerings into new areas or products; the ability to commercialize technology; unexpected occurrences that deter the full documentation and “bring to market” plan for products; trends and fluctuations in the industry; changes in demand and purchasing volume of customers; unpredictability of suppliers; the ability to attract and retain qualified personnel and the ability to move product sales to production levels; changes in domestic and foreign business, market, financial, political, and legal conditions; the uncertainty of projected financial information; delays caused by factors outside of our control; changes in our ability to successfully receive purchase orders and generate revenue under our existing contracts with partners and distributors; our ability to realize the benefits of the strategic partnerships; the identified material weakness in our internal controls over financial reporting (including the timeline to remediate the material weakness); the rollout of the business and the timing of expected business milestones; the effects of competition on our future business; our ability to obtain and access financing in the future; our ability to pay our debt obligations as they come due; and those factors discussed in the Company’s reports and other documents filed with the SEC, including under the heading “Risk Factors.” If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that QT Imaging presently does not know or that QT Imaging currently believes are immaterial which could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect QT Imaging’s expectations, plans or forecasts of future events and views as of the date of this release. QT Imaging anticipates that subsequent events and developments will cause QT Imaging’s assessments to change. However, while QT Imaging may elect to update these forward-looking statements at some point in the future, QT Imaging specifically disclaims any obligation to do so. Accordingly, undue reliance should not be placed upon the forward-looking statements.

[Financial tables below]

Summary of Results

For the Three and Six Months Ended June 30, 2026 and 2025

(Unaudited)

 

Three Months Ended

June 30,

 

Six Months Ended

June 30,

$ thousands (except per share amounts)

 

2026

 

 

 

2025

 

 

 

2026

 

 

 

2025

 

Revenue

$

7,435

 

 

$

3,659

 

 

$

13,965

 

 

$

6,458

 

Cost of revenue

 

4,375

 

 

 

1,832

 

 

 

8,233

 

 

 

2,819

 

Gross profit

 

3,060

 

 

 

1,827

 

 

 

5,732

 

 

 

3,639

 

Operating expenses:

 

 

 

 

 

 

 

Research and development

 

1,624

 

 

 

901

 

 

 

3,348

 

 

 

1,753

 

Selling, general and administrative

 

3,300

 

 

 

1,969

 

 

 

6,597

 

 

 

3,971

 

Total operating expenses

 

4,924

 

 

 

2,870

 

 

 

9,945

 

 

 

5,724

 

Loss from operations

 

(1,864

)

 

 

(1,043

)

 

 

(4,213

)

 

 

(2,085

)

Interest and other expense, net:

 

 

 

 

 

 

 

Interest expense, net

 

(745

)

 

 

(379

)

 

 

(1,675

)

 

 

(1,070

)

Other (expense) income, net

 

(4

)

 

 

9

 

 

 

(8

)

 

 

24

 

Change in fair value of warrant liability

 

89

 

 

 

(2,796

)

 

 

(84

)

 

 

(3,501

)

Change in fair value of derivative liability

 

 

 

 

 

 

 

 

 

 

101

 

Change in fair value of earnout liability

 

(250

)

 

 

210

 

 

 

(200

)

 

 

160

 

Loss on issuance of debt

 

 

 

 

 

 

 

 

 

 

(6,640

)

Loss on debt extinguishment and modification

 

(8,294

)

 

 

 

 

 

(8,294

)

 

 

(2,124

)

Total interest and other expenses, net

 

(9,204

)

 

 

(2,956

)

 

 

(10,261

)

 

 

(13,050

)

Loss before income tax expense

 

(11,068

)

 

 

(3,999

)

 

 

(14,474

)

 

 

(15,135

)

Income tax expense

 

2

 

 

 

3

 

 

 

2

 

 

 

3

 

Net loss

$

(11,070

)

 

$

(4,002

)

 

$

(14,476

)

 

$

(15,138

)

Net loss attributable to common stockholders

$

(11,070

)

 

$

(4,002

)

 

$

(14,476

)

 

$

(15,138

)

 

 

 

 

 

 

 

 

Net loss per share – basic and diluted (1)

$

(0.75

)

 

$

(0.42

)

 

$

(1.01

)

 

$

(1.63

)

 

 

 

 

 

 

 

 

Weighted-average shares outstanding (1)

 

14,831

 

 

 

9,451

 

 

 

14,317

 

 

 

9,312

(1) Share and per share amounts for the three and six months ended June 30, 2025 differ from those published in prior unaudited condensed consolidated financial statements as they were retrospectively adjusted as a result of the Reverse Stock Split. Specifically, the number of shares of common stock outstanding during periods before the Reverse Stock Split are divided by the exchange ratio of 3:1, such that each three shares of common stock were combined and reconstituted into one share of common stock effective October 23, 2025.

EBITDA and Adjusted EBITDA

For the Three and Six Months Ended June 30, 2026 and 2025

(Unaudited)

 

Three Months Ended

June 30,

 

Six Months Ended June 30,

$ thousands

 

2026

 

 

 

2025

 

 

 

2026

 

 

 

2025

 

Net loss

$

(11,070

)

 

$

(4,002

)

 

$

(14,476

)

 

$

(15,138

)

Income tax expense

 

2

 

 

 

3

 

 

 

2

 

 

 

3

 

Interest expense, net

 

745

 

 

 

379

 

 

 

1,675

 

 

 

1,070

 

Depreciation and amortization

 

21

 

 

 

38

 

 

 

41

 

 

 

76

 

EBITDA

 

(10,302

)

 

 

(3,582

)

 

 

(12,758

)

 

 

(13,989

)

Other expense (income), net

 

4

 

 

 

(9

)

 

 

8

 

 

 

(24

)

Change in fair value of warrant liability (1)

 

(89

)

 

 

2,796

 

 

 

84

 

 

 

3,501

 

Change in fair value of derivative liability (2)

 

 

 

 

 

 

 

 

 

 

(101

)

Change in fair value of earnout liability (3)

 

250

 

 

 

(210

)

 

 

200

 

 

 

(160

)

Loss on issuance of debt (4)

 

 

 

 

 

 

 

 

 

 

6,640

 

Loss on debt extinguishment and modification (5)

 

8,294

 

 

 

 

 

 

8,294

 

 

 

2,124

 

Stock-based compensation

 

668

 

 

 

219

 

 

 

1,049

 

 

 

320

 

Adjusted EBITDA

$

(1,175

)

 

$

(786

)

 

$

(3,123

)

 

$

(1,689

)

(1) The change in fair value of warrant liability during the three and six months ended June 30, 2026 relates to the change in the market value of the private warrants outstanding as of June 30, 2026. The change in fair value of warrant liability during the three and six months ended June 30, 2025 relates to the change in the market value of the private placement warrants outstanding as of June 30, 2025, as well as the change in market value of the Lynrock Lake Warrant and Yorkville Warrant, which were revalued and reclassified to equity on June 11, 2025.

(2) The change in fair value of derivative liability during the six months ended June 30, 2025 relates to the Yorkville Pre-paid Advance, which contained features that were bifurcated as freestanding financial instruments and initially valued on March 4, 2024 upon consummation of the Merger. The derivative liability was subsequently revalued as of February 26, 2025, prior to the extinguishment of the Yorkville Note.

(3) The earnout liability relates to the contingent consideration for the Merger Earnout Consideration Shares pursuant to the Business Combination Agreement dated December 8, 2022, as amended in September 2023. The earnout liability was initially valued using the Monte Carlo Simulation method on March 4, 2024 and subsequently revalued using the same method as of June 30, 2026 and 2025.

(4) Upon the issuance of the Lynrock Lake Term Loan, which closed on February 26, 2025, the Company recorded a loss of $6.6 million, including debt issuance costs of $0.2 million, during the six months ended June 30, 2025.

(5) The Company recorded a loss on debt extinguishment of $8.3 million during the three and six months ended June 30, 2026 as a result of the modification of the Lynrock Lake Term Loan on May 12, 2026, which extended the maturity date from March 2027 to March 2029 and increased the interest rate from 10% to 12%. The Company recorded debt modification expense of $0.1 million during the six months ended June 30, 2025 due to the modification of the Cable Car Note on January 9, 2025, and debt extinguishment expense of $2.0 million due to the extinguishment of the Yorkville Note and Cable Car Note on February 26, 2025.

Consolidated Balance Sheets

As of June 30, 2026 and December 31, 2025

(Unaudited)

$ in thousands

June 30,

2026

 

December 31,

2025

Assets

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

10,924

 

 

$

10,412

 

Restricted cash and cash equivalents

 

50

 

 

 

50

 

Accounts receivable, net

 

7,404

 

 

 

5,781

 

Inventory

 

9,870

 

 

 

5,027

 

Prepaid expenses and other current assets

 

1,171

 

 

 

821

 

Total current assets

 

29,419

 

 

 

22,091

 

 

 

 

 

Property and equipment, net

 

793

 

 

 

318

 

Operating lease right-of-use assets, net

 

379

 

 

 

573

 

Other assets

 

39

 

 

 

39

 

Total assets

$

30,630

 

 

$

23,021

 

 

 

 

 

Liabilities and Stockholders’ Equity

 

 

 

Current liabilities:

 

 

 

Accounts payable

$

3,011

 

 

$

3,580

 

Accrued expenses and other current liabilities

 

6,051

 

 

 

3,825

 

Current maturities of long-term debt

 

 

 

 

9

 

Operating lease liabilities, current

 

437

 

 

 

454

 

Total current liabilities

 

9,499

 

 

 

7,868

 

Long-term debt

 

11,397

 

 

 

683

 

Related party notes payable

 

3,895

 

 

 

3,895

 

Operating lease liabilities

 

 

 

 

203

 

Warrant liability

 

187

 

 

 

103

 

Earnout liability

 

2,410

 

 

 

2,210

 

Other liabilities

 

996

 

 

 

1,614

 

Total liabilities

 

28,384

 

 

 

16,576

 

 

 

 

 

Stockholders’ equity:

 

 

 

Common stock

 

1

 

 

 

1

 

Additional paid-in capital

 

69,745

 

 

 

59,468

 

Accumulated deficit

 

(67,500

)

 

 

(53,024

)

Total stockholders’ equity

 

2,246

 

 

 

6,445

 

Total liabilities and stockholders’ equity

$

30,630

 

 

$

23,021

Consolidated Statements of Cash Flows

For the Six Months Ended June 30, 2026 and 2025

(Unaudited)

 

Six Months Ended June 30,

$ in thousands

 

2026

 

 

 

2025

 

Cash flows from operating activities:

 

 

 

Net loss

$

(14,476

)

 

$

(15,138

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

Depreciation and amortization

 

41

 

 

 

76

 

Stock-based compensation

 

1,049

 

 

 

320

 

Loss on issuance of debt

 

 

 

 

6,640

 

Loss on debt extinguishment and modification

 

8,294

 

 

 

2,124

 

Non-cash interest

 

1,123

 

 

 

548

 

Non-cash operating lease

 

(26

)

 

 

(19

)

Change in fair value of warrant liability

 

84

 

 

 

3,501

 

Change in fair value of derivative liability

 

 

 

 

(101

)

Change in fair value of earnout liability

 

200

 

 

 

(160

)

Changes in operating assets and liabilities:

 

 

 

Accounts receivable

 

(1,623

)

 

 

(3,584

)

Inventory

 

(4,072

)

 

 

(90

)

Prepaid expenses and other current assets

 

(350

)

 

 

(1,227

)

Accounts payable

 

(396

)

 

 

772

 

Accrued expenses and other current liabilities

 

982

 

 

 

924

 

Other liabilities

 

679

 

 

 

435

 

Net cash used in operating activities

 

(8,491

)

 

 

(4,979

)

 

 

 

 

Cash flows from investing activities:

 

 

 

Purchases of property and equipment

 

(191

)

 

 

(47

)

Net cash used in investing activities

 

(191

)

 

 

(47

)

 

 

 

 

Cash flows from financing activities:

 

 

 

Proceeds from sale of common stock and warrants

 

9,305

 

 

 

700

 

Proceeds from long-term debt, net of issuance costs

 

 

 

 

10,000

 

Proceeds from stock option exercises

 

246

 

 

 

 

Repayment of long-term debt

 

(9

)

 

 

(4,674

)

Payments for taxes related to net settlement of equity awards

 

(63

)

 

 

 

Payment of stock issuance costs

 

(285

)

 

 

 

Payment of debt issuance costs

 

 

 

 

(150

)

Net cash provided by financing activities

 

9,194

 

 

 

5,876

 

Net increase in cash and cash equivalents and restricted cash and cash equivalents

 

512

 

 

 

850

 

Cash and cash equivalents and restricted cash and cash equivalents, beginning balance

 

10,462

 

 

 

1,192

 

Cash and cash equivalents and restricted cash and cash equivalents, ending balance

$

10,974

 

 

$

2,042

 

 

Investors

CORE IR

Tirth Patel

[email protected]

386-295-2215

Media

CORE IR

Matthew Cossel

[email protected]

212-655-0924

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Technology Biotechnology Health Other Health Radiology Artificial Intelligence Oncology Other Science Other Technology Research Medical Devices Software Hardware Science

MEDIA:

(In millions, except percentages) Q2 FY26   Q1 FY26   Q2 FY25   Q/Q Change   Y/Y Change
Revenue $ 220     $ 206     $ 162     7 %   35 %
Net income (loss) $ (4 )   $ 49     $ (24 )   NM   (82 )%
Adjusted EBITDA1 $ 132     $ 120     $ 85     10 %   55 %
Net income (loss) Margin (2 )%     24 %   (15 )%   NM   13 pts
Adjusted EBITDA Margin1   60 %     58 %     53 %   2 pts   8 pts

_________
Note: Variances that are not meaningful (“NM”) are not presented in the table above. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

“Q2 marked our eleventh consecutive quarter of revenue growth and reinforced a pattern we have seen over time: better advertising performance gives customers reason to increase their spend with us. Cortex’s continued self-learning and discrete model improvements both contributed to that performance this quarter,” said Jeremy Bondy, Liftoff’s Chief Executive Officer. “Our integrated advertising platform, powered by Cortex machine learning, is designed to serve all verticals in the app economy, and we believe we’re still in the early innings of our growth story in a large, expanding, and structurally under-monetized market.”

“Our strong financial results reflect the durability of our financial model,” added Tarek Kutrieh, Liftoff’s President and Chief Financial Officer. “Adjusted EBITDA margin expanded meaningfully, as our revenue scaled faster than our cost base. That operating leverage, combined with our capital light architecture, converted growth into significant free cash flow. We see a clear opportunity for continued sustainable, profitable growth.”

Business
Highlights
:

  • Core Advertising Revenue2 was $219 million in the second quarter, an increase of 36% year-over-year and 7% quarter-over-quarter.
  • Core Advertising Daily Average Revenue (DAR)2 increased by 6% quarter-over-quarter.
  • Net Loss of $(4) million in the second quarter is inclusive of $45 million of non-cash expenses related to our IPO and other capital markets activities.
  • Trailing 12-month Net Cash from Operating Activities was $237 million, an increase of 90% from the corresponding period of the prior year.
  • Trailing 12-month Free Cash Flow1 was $184 million, an increase of 142% from the corresponding period of the prior year.

Third
Quarter
2026
Financial Guidance Summary
3

(In millions, except percentages) Low   High
Revenue $ 217     $ 222  
Adjusted EBITDA $ 124     $ 128  
Adjusted EBITDA Margin   57 %     58 %
               

Fiscal Year
2026
Financial Guidance Summary
3

(In millions, except percentages) Low   High
Revenue $ 870     $ 880  
Adjusted EBITDA $ 510     $ 518  
Adjusted EBITDA Margin   59 %     59 %

_________
1 For a discussion on how we define, use, and calculate these non-GAAP financial measures and a reconciliation thereof to the most directly comparable GAAP financial measures, see “Key Operating and Financial Metrics” and the tables at the end of this press release.
2 See “Key Operating and Financial Metrics” for additional information on how we define Core Advertising Revenue and Core Advertising DAR.
3 We have not provided the most comparable GAAP metric or a GAAP reconciliation for certain forward-looking non-GAAP metrics—specifically Adjusted EBITDA and Adjusted EBITDA margin—as a result of the uncertainty regarding, and the potential variability of, reconciling items such as stock-based compensation expense. Accordingly, a reconciliation of these non-GAAP guidance metrics to their corresponding GAAP equivalents is not available without unreasonable effort. However, it is important to note that material changes to reconciling items could have a significant effect on future GAAP results.

Conference Call Information

The Company will host a conference call today at 2:00 PM PT / 5:00 PM ET during which management will discuss the Company’s quarterly results and provide commentary on business performance. The call will be hosted by Jeremy Bondy, Chief Executive Officer, and Tarek Kutrieh, President and Chief Financial Officer.

The conference call may be accessed on the Company’s website at: https://investors.liftoff.ai. A replay will also be available under the ‘News & Events’ section of the Company’s Investor Relations website.


About Liftoff

Liftoff (NASDAQ: LFTO) is a leading growth and monetization engine built for the mobile app economy. Its AI-powered platform, Cortex™, unifies marketing, creative, and monetization to deliver measurable performance at scale across the app lifecycle. Liftoff enables advertisers to unlock profitable user growth while helping app publishers maximize revenue with advanced ad monetization technology. Founded in 2012 and headquartered in Redwood City, California, Liftoff supports a diverse, global customer base across gaming, consumer, and emerging app categories.


Contacts

Investor Relations

Jenn Kettnich
[email protected]
Media Relations

Laura Wilkinson
[email protected]
   


CAUTIONARY NOTE ABOUT FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include all statements that are not historical facts. Forward-looking statements include, but are not limited to, statements about: (1) projections of revenues, expenses, income or loss, earnings or loss per share, cash flow, margins, profitability, capital expenditures, liquidity, capital resources or other financial or operating items; (2) our plans, strategies and objectives, including those relating to our business model, growth strategy, market opportunity, customer retention and expansion, acquisition of new customers, technology innovation, Cortex and AI-related initiatives; (3) future financial or operating performance; (4) our expectations regarding macroeconomic conditions, market trends, competition, regulatory developments, taxes, public company costs, indebtedness, interest rates and other risks affecting our business; (5) our expectations regarding acquisitions, investments, dispositions, financings or other strategic transactions we may pursue; and (6) assumptions underlying any of the foregoing. We may, in some cases, use words such as “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “foreseeable,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “seek,” “should,” “will,” or “would,” or similar words or phrases that convey uncertainty of future events or outcomes, to identify forward-looking statements in this press release. Factors that may cause actual results to differ from expected results include those described in our filings with the Securities and Exchange Commission (the “SEC”), including those set forth in the “Risk Factors” section in our final prospectus (the “IPO Prospectus”) filed with the SEC on June 4, 2026 pursuant to Rule 424(b)(4) under the Securities Act relating to our registration statement on Form S-1 (File No. 333-295144).

The forward-looking statements contained in this press release are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Although we believe that the assumptions underlying the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. There are a number of factors, many of which are beyond our control, that could cause actual results to differ materially from the results anticipated by these forward-looking statements, including, among others, risks related to: our ability to retain existing customers, expand customer usage and attract new customers; the fact that we generally do not have long-term commitments from customers; advertiser demand, marketing budgets, customer churn or consolidation, and broader macroeconomic, market, public health and geopolitical conditions, including inflation, interest rates, tariffs and U.S.-China tensions; our dependence on mobile operating systems, app stores, large internet and technology companies, third-party platforms, cloud infrastructure providers, supply partners and other participants in the mobile advertising ecosystem; competition and rapid changes in technology, industry standards and customer needs; our ability to collect, use, disclose and otherwise process data, and evolving privacy, data protection, information security, consumer protection, advertising, tracking, targeting, protection of minors, AI and other legal and regulatory requirements; fraud, malware, cybersecurity incidents, system failures, service interruptions and other technical or operational disruptions; our ability to maintain and scale our technology, including Cortex and other AI capabilities, and develop and introduce new products and services; changes in app store policies, user opt-in or opt-out choices, ad-blocking technologies and other limitations on mobile advertising; our reliance on the continued growth and health of the mobile app ecosystem, including mobile gaming and the broader app economy; fluctuations in our operating results, revenue concentration, market opportunity estimates and key metrics; international operations, including risks associated with China, trade controls, tariffs, sanctions, anti-corruption laws and foreign currency exchange; our ability to attract, retain and motivate key personnel and sales teams and manage public company costs; acquisitions, investments, partnerships, financings and other strategic transactions; tax matters, accounting standards, estimates, goodwill or other impairment, stock-based compensation and internal controls, including the material weakness identified in our internal control over financial reporting; legal proceedings and intellectual property and open source software matters; ownership concentration and risks related to our common stock, including stock price volatility, future sales and dilution; and our substantial indebtedness, restrictive debt covenants, interest rate exposure, debt service obligations, liquidity and ability to raise additional capital. This list is not exhaustive. For a more detailed discussion of these and other factors, see the “Risk Factors” section in the IPO Prospectus. These factors should not be construed as exhaustive. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, our actual results may vary in material respects from those expressed or implied in these forward-looking statements.

The forward-looking statements included in this press release speak only as of the date of this press release or as of the date they are made, as applicable. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, investments, or other strategic transactions we may make. Except as otherwise required by law, we disclaim any intent or obligation to update any “forward-looking statement” made in this press release to reflect changed assumptions, the occurrence of unanticipated events, or changes to future operating results over time.


Key Operating and Financial Metrics

We monitor the following key metrics to help us evaluate the health of our business, identify trends affecting our growth, formulate goals and objectives and make strategic decisions. We believe these non-GAAP and operational measures are useful in evaluating our performance, in addition to our financial results prepared in accordance with GAAP.

Our definitions may differ from the definitions used by other companies and therefore comparability may be limited. In addition, other companies, including peer companies, may not publish these or similar metrics. Thus, our non-GAAP financial measures should be considered in addition to, not as substitutes for, or in isolation from, measures prepared in accordance with GAAP. We also strongly urge you to review the reconciliation to the corresponding GAAP financial measures set forth at the end of this press release. To properly and prudently evaluate our business, we encourage you to review Liftoff’s financial information in its entirety and not to rely on a single financial measure to evaluate our business.


Adjusted EBITDA and Adjusted EBITDA Margin

We report our financial results in accordance with GAAP, however, management believes that Adjusted EBITDA and Adjusted EBITDA Margin, which are non-GAAP measures, provide users of our financial information with useful supplemental information enabling a comparison of our performance across periods. We believe Adjusted EBITDA and Adjusted EBITDA Margin provide visibility to the underlying continuing operating performance of our business. Management uses Adjusted EBITDA and Adjusted EBITDA Margin to evaluate and manage the performance of our business, make resource allocation decisions, and compensate key personnel as they provide further understanding with respect to the results of our operations.

We define Adjusted EBITDA as net income adjusted for interest expense, net, income tax expense, depreciation and amortization expense, stock-based compensation, other expenses, net, and further adjusted for certain items that impact comparison of the performance of our businesses either period-over period or with other businesses as more fully described below. We also disclose Adjusted EBITDA Margin, which is calculated as Adjusted EBITDA divided by revenue.

Adjusted EBITDA and Adjusted EBITDA Margin are non-GAAP financial measures and are presented for supplemental informational purposes only and should not be considered as alternatives or substitutes to financial information presented in accordance with GAAP. These measures have certain limitations in that they do not include the impact of certain expenses that are reflected in our condensed consolidated statements of operations that are necessary to run our business. Our definitions may differ from the definitions used by other companies and therefore comparability may be limited. In addition, other companies may not publish these or similar metrics. Thus, our Adjusted EBITDA and Adjusted EBITDA Margin should be considered in addition to, not as substitutes for, or in isolation from, measures prepared in accordance with GAAP. Some of the limitations and other factors to consider include:

  • Adjusted EBITDA and Adjusted EBITDA Margin exclude the recurring, non-cash expenses of depreciation and amortization of property and equipment, capitalized internal-use software, and definite-lived intangible assets, and although these are non-cash expenses, the assets being depreciated and amortized may have to be replaced in the future;
  • Adjusted EBITDA and Adjusted EBITDA Margin do not reflect changes in or cash requirements for our working capital needs;
  • Adjusted EBITDA and Adjusted EBITDA Margin exclude stock-based compensation expense, which has been, and will continue to be for the foreseeable future, an important part of how we attract and retain our employees and a significant recurring expense in our business;
  • Adjusted EBITDA and Adjusted EBITDA Margin do not reflect the interest expense, net or the cash requirements to service interest or principal payments on our indebtedness;
  • Adjusted EBITDA and Adjusted EBITDA Margin exclude the non-cash charges related to debt extinguishments, impairments of primarily capitalized internal-use software, and revaluation of contingent consideration, as these impact the comparability of our business across periods and do not relate to the continuing operating performance of our business;
  • Adjusted EBITDA and Adjusted EBITDA Margin exclude costs related to IPO, integration, non-recurring transactions and expenses, and reorganization severance costs, as these impact the comparability of our business across periods and do not relate to the continuing operating performance of our business;
  • Adjusted EBITDA and Adjusted EBITDA Margin do not reflect our income tax expense provision; and
  • Adjusted EBITDA and Adjusted EBITDA Margin exclude other expenses, net, which primarily relate to non-operating foreign exchange gains and losses.

Adjusted EBITDA is not a liquidity measure and should not be considered as discretionary cash available to us to reinvest in the growth of our business or to distribute to stockholders or as a measure of cash that will be available to us to meet our obligations.


Free Cash Flow

We define Free Cash Flow as net cash provided by operating activities less purchase and capitalization of property, equipment and software. We subtract purchase and capitalization of property, equipment and software in our calculation of Free Cash Flow as we believe these expenditures represent ongoing investments required to support and grow our business. Our definition may differ from the definitions used by other companies and therefore comparability may be limited. In addition, other companies may not publish Free Cash Flow or similar metrics. Thus, our Free Cash Flow, which is a non-GAAP measure, should be considered in addition to, not as a substitute for, or in isolation from, measures prepared in accordance with GAAP.

Free Cash Flow is a measure of liquidity that provides useful information to our management, investors and others in understanding and evaluating the strength of our liquidity and future ability to generate cash that can be used for strategic opportunities, including investing in our business. Free Cash Flow has certain limitations in that it does not represent our residual cash flow for discretionary expenditures and our non-discretionary commitments. Free Cash Flow is not necessarily a measure of our ability to fund our cash needs.


Core Advertising Revenue

Core Advertising Revenue represents revenue generated from our current advertising platforms, which are predominantly powered by Cortex-backed demand solutions. Core Advertising represents the foundation of our business moving forward, reflecting our strategic focus on Cortex-enabled solutions and anticipated long-term growth within performance advertising. We believe Core Advertising revenue, and its historical growth, is an important metric as it aligns with the rollout of Cortex in 2023 and is more representative of our growth potential versus total revenue in historical periods.


Core Advertising Daily Average Revenue

Core Advertising Daily Average Revenue (“DAR”) is calculated by dividing Core Advertising Revenue by the number of calendar days during the reporting period. We believe DAR provides investors with useful information about the performance of our core advertising business and a normalized measure of revenue that facilitates comparisons across reporting periods with differing numbers of calendar days.

 
Liftoff Mobile, Inc.

Condensed Consolidated Balance Sheets

As of June 30, 2026 and December 31, 2025
(In thousands, except share and per share data)
(Unaudited)
 
  As of
  June 30,
2026
  December 31,
2025
ASSETS
Current assets:      
Cash and cash equivalents $ 305,398     $ 133,306  
Accounts receivable, net   366,112       355,277  
Income tax receivable   995       1,651  
Prepaid expenses and other current assets   20,498       26,891  
Total current assets   693,003       517,125  
Restricted cash   789       789  
Property, equipment, and software, net   128,984       115,968  
Intangible assets, net   153,313       178,677  
Goodwill   1,056,302       1,057,180  
Other assets   33,571       31,590  
Total assets $ 2,065,962     $ 1,901,329  
LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS’ EQUITY (DEFICIT)      
Current liabilities:      
Accounts payable $ 355,096     $ 356,519  
Accrued liabilities   99,294       77,216  
Current portion of long-term debt   18,550       18,550  
Other current liabilities   30,274       29,169  
Total current liabilities   503,214       481,454  
Deferred tax liability   40,813       29,009  
Long-term debt, net   1,392,149       1,801,150  
Other liabilities   135,320       126,597  
Total liabilities   2,071,496       2,438,210  
       
Redeemable convertible preferred stock:      
Series A redeemable convertible preferred stock ($0.0001 par value – Nil and 1,000,000 shares authorized as of June 30, 2026 and December 31, 2025, respectively; Nil and 425,000 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively) Liquidation preference of nil and $425,000 as of June 30, 2026 and December 31, 2025, respectively.         414,607  
       
Stockholders’ equity (deficit):      
Preferred stock ($0.0001 par value – 700,000,000 and nil shares authorized as of June 30, 2026 and December 31, 2025, respectively, no shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively)          
Common Stock ($0.0001 par value – 7,000,000,000 and 234,000,000 shares authorized as of June 30, 2026 and December 31, 2025, respectively; 169,330,527 and 123,002,518 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively)   17       12  
Additional paid-in capital   906,720       5,867  
Accumulated other comprehensive loss   (1,400 )     (1,396 )
Accumulated deficit   (910,871 )     (955,971 )
Total stockholders’ equity (deficit)   (5,534 )     (951,488 )
Total liabilities, redeemable convertible preferred stock, and stockholders’ equity (deficit) $ 2,065,962     $ 1,901,329  

 
Liftoff Mobile, Inc.

Condensed Consolidated Statements of Operations

For the three and six months ended June 30, 2026 and 2025
(In thousands, except share and per share data)
(Unaudited)
 
  Three Months Ended June 30,   Six Months Ended June 30,
    2026       2025       2026       2025  
Revenue $ 219,505     $ 162,084     $ 425,147     $ 312,053  
Costs and operating expenses:              
Cost of revenue, excluding depreciation and amortization   29,033       25,455       57,018       48,963  
General and administrative   34,991       58,391       59,834       79,113  
Research and development   34,513       36,925       61,887       57,849  
Sales and marketing   20,594       16,149       38,329       30,411  
Depreciation and amortization   22,963       25,120       44,731       50,672  
Total costs and operating expenses   142,094       162,040       261,799       267,008  
Income from operations   77,411       44       163,348       45,045  
Other income (expense):              
Interest expense, net   (33,339 )     (30,038 )     (68,314 )     (59,642 )
Loss on debt extinguishment   (7,366 )           (7,366 )      
Post-conversion earnout share liability revaluation   139             2,675        
Contingent consideration revaluation   (17,529 )     3,300       (12,629 )     (5,100 )
Other (expense) income, net   (86 )     (1,137 )     (198 )     (992 )
Income (loss) before income taxes   19,230       (27,831 )     77,516       (20,689 )
Income tax (expense) benefit   (23,461 )     4,048       (32,416 )     774  
Net income (loss) $ (4,231 )   $ (23,783 )   $ 45,100     $ (19,915 )
               
Net income (loss) per share:              
Basic $ (0.03 )   $ (0.16 )   $ 0.30     $ (0.14 )
Diluted $ (0.03 )   $ (0.16 )   $ 0.27     $ (0.14 )
               
Weighted average common shares used to compute net income (loss) per share attributable to common stockholders:              
Basic   137,076,788       145,269,540       130,121,241       145,309,595  
Diluted   137,076,788       145,269,540       143,533,326       145,309,595  

 
Liftoff Mobile, Inc.
Condensed Consolidated Statements of Cash Flows
For the six months ended June 30, 2026 and 2025
(In thousands)
(Unaudited)
 
  Six Months Ended June 30,
    2026       2025  
Cash flows from operating activities:      
Net income (loss) $ 45,100     $ (19,915 )
Adjustments to reconcile net income (loss) to net cash provided by operating activities:      
Depreciation and amortization   44,731       50,672  
Amortization of debt issuance costs   2,198       3,219  
Provision for credit losses   1,995       1,542  
Stock-based compensation expense   26,634       4,022  
Non-cash lease expense   2,489       2,459  
Deferred income tax   13,022       (6,007 )
Loss on debt extinguishment   7,366        
Contingent consideration revaluation   12,629       5,100  
Post-conversion earnout share liability revaluation   (2,675 )      
Change in operating assets and liabilities:      
Accounts receivable   (12,780 )     (63,806 )
Income tax receivable   618       132  
Prepaid expenses and other current assets   3,522       (11,205 )
Other assets   (2,889 )     (1,501 )
Accounts payable   (8,006 )     79,681  
Accrued liabilities   20,488       28,401  
Other current liabilities   1,430       1,173  
Other long-term liabilities   (4,395 )     3,930  
Net cash provided by operating activities   151,477       77,897  
Cash flows from investing activities:      
Purchase and capitalization of property, equipment and software   (27,247 )     (24,901 )
Net cash used in investing activities   (27,247 )     (24,901 )
Cash flows from financing activities:      
Proceeds from the exercise of stock options   2,255       1,237  
Proceeds from issuance of preferred stock         409,545  
Proceeds from post-conversion earnout share liability         5,393  
Proceeds from initial public offering, net of underwriting discounts and commissions   472,397        
Repurchase of common stock         (383,389 )
Payment of debt principal   (418,438 )     (7,563 )
Payment of deferred offering costs   (8,359 )      
Net cash provided by financing activities   47,855       25,223  
Effect of exchange rate on cash, cash equivalents, and restricted cash   7       663  
Net increase in cash, cash equivalents, and restricted cash   172,092       78,882  
Cash, cash equivalents, and restricted cash, beginning of period   134,095       99,088  
Cash, cash equivalents, and restricted cash, end of period $ 306,187     $ 177,970  
               

Liftoff Mobile, Inc.

Reconciliation of Net Income (Loss) to Adjusted EBITDA

For the three and six months ended June 30, 2026 and 2025

The following table reconciles net income (loss) and net income (loss) margin, the most comparable GAAP financial measures to Adjusted EBITDA and Adjusted EBITDA Margin, respectively, for the periods presented:

    Three Months Ended June 30,   Six Months Ended June 30,
(in thousands, except percentages)     2026       2025       2026       2025  
Net income (loss)   $ (4,231 )   $ (23,783 )   $ 45,100     $ (19,915 )
Interest expense, net     33,339       30,038       68,314       59,642  
Income tax (expense) benefit     23,461       (4,048 )     32,416       (774 )
Depreciation and amortization     22,963       25,120       44,731       50,672  
Stock-based compensation expense (a)     28,223       21,854       34,834       25,685  
Contingent consideration revaluation     17,529       (3,300 )     12,629       5,100  
Other (expense) income, net     86       1,137       198       992  
Reorganization severance costs (b)           548             592  
Transaction costs(c)     (468 )     35,860       (468 )     36,911  
Other non-recurring expenses (d)     4,183       1,746       9,952       4,134  
Loss on debt extinguishment (e)     7,366             7,366        
Post-conversion earnout share liability revaluation     (139 )           (2,675 )      
Adjusted EBITDA   $ 132,312     $ 85,172     $ 252,397     $ 163,039  
Net income (loss) Margin   (2 )%   (15 )%     11 %   (6 )%
Adjusted EBITDA Margin     60 %     53 %     59 %     52 %

_________
(a) Stock-based compensation includes $3.9 million and $2.9 million related to the vesting and payment of the 2021, 2024, and 2025 Distributions to employee equity holders for the three months ended June 30, 2026 and 2025, respectively, as well as $8.2 million and $6.1 million for the six months ended June 30, 2026 and 2025, respectively. Distributions of this nature are not expected to reoccur as a public company.
(b) Represents reorganization costs associated with the integration of legacy Liftoff and Vungle operations following the 2021 merger. As a result of the Company’s integration activities, the Company undertook multiple defined reduction-in-force programs to eliminate duplicative roles and streamline the Company’s workforce across all functions. The costs came primarily in the form of severance and professional service costs associated with such operating model redesign, including severance related expenses and professional fees. Reorganization costs relating to these integration activities are expected to be minimal following the 2025 fiscal year. 
(c) Represents costs for transaction-related services, such as investment banking, legal, accounting, and diligence, primarily incurred in connection with capital markets activities, including debt refinancing efforts and General Atlantic’s investment. 
(d) Represents non-recurring third-party professional fees in preparation of becoming a public company that were not capitalizable. 
(e) Consisted of a write-off of $7.4 million of unamortized issuance costs.

Liftoff Mobile, Inc.

Reconciliation of Net Cash Provided By Operating Activities to Free Cash Flow

For the twelve months ended June 30, 2026 and 2025

The following table reconciles net cash provided by operating activities, the most comparable GAAP financial measure to Free Cash Flow for the periods presented:

  Twelve Months Ended June 30,
(in thousands)   2026       2025  
Net cash provided by operating activities $ 236,934     $ 124,688  
Less:      
Purchase and capitalization of property, equipment and software   (52,481 )     (48,323 )
Free Cash Flow $ 184,453     $ 76,365  
Net cash used in investing activities $ (52,481 )   $ (48,323 )
Net cash used in financing activities $ (55,941 )   $ (105,501 )



Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights

– ALTO-207 development expanded: an additional Phase 3 trial evaluating ALTO-207 as monotherapy in treatment-resistant depression (TRD) is now planned, alongside the ongoing potentially registrational Phase 2b trial; topline Phase 2b data on track for 2H 2027 –

– Independent investigator-led study results published in Nature Medicine reinforce the dopaminergic mechanism underlying ALTO-207, demonstrating significant effects on anhedonia (Hedges’ g=0.62, p=0.006) –

– Approximately $100 million financing completed in July 2026; pro forma cash of approximately $338 million expected to fund planned operations through 2030 –

MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–
Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended June 30, 2026, and highlighted recent progress across its pipeline of clinical-stage product candidates.

“The second quarter further strengthened the case for ALTO-207 and our conviction in the opportunity ahead of it,” said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience. “The Nature Medicine publication of PRIME-PRAXOL provides another independent, peer-reviewed dataset showing that dopaminergic treatment produces large effects in depression, and, just as importantly, a reminder of the tolerability challenge that ALTO-207 is designed to address. With enrollment in our potentially registrational Phase 2b trial tracking as planned and pro forma cash of approximately $338 million, we are now positioned to pursue ALTO-207 in both the adjunctive and monotherapy settings, broadening the potential label and the commercial opportunity, with expected runway through 2030.”

Second Quarter and Recent Pipeline Highlights

ALTO-207: Independent Nature Medicine publication reinforces mechanism; monotherapy Phase 3 trial added to development plan

ALTO-207 is a fixed-dose combination of pramipexole, a dopamine D3-preferring D3/D2 agonist with demonstrated antidepressant effect across multiple independent trials, and ondansetron, a selective 5-HT3 receptor antagonist. The fixed-dose combination is designed to enable rapid titration to higher pramipexole doses by mitigating the dose-limiting nausea and vomiting associated with pramipexole. This combination approach — and its use to enable higher pramipexole dosing in the treatment of depression — is the subject of Alto’s issued method-of-treatment patent estate described below. ALTO-207 is being developed to address the significant unmet medical need in TRD, which is estimated to affect approximately 7 million adults in the United States.

  • In June 2026, results from PRIME-PRAXOL — an independent, randomized, double-blind, placebo-controlled trial conducted by investigators at Lund University, Sweden — were published in Nature Medicine. Adults with major depressive disorder (MDD), dysthymia, or bipolar depression and clinically significant anhedonia received flexible-dose pramipexole or placebo added to ongoing treatment for nine weeks, followed by a six-month open-label extension.

    • The trial met its primary endpoint, with pramipexole reducing anhedonia significantly more than placebo on the Snaith–Hamilton Pleasure Scale (SHAPS) (mean difference −4.04; 95% CI −6.89 to −1.18; p=0.006; Hedges’ g=0.62).

    • Significant improvements were also observed on independent measures of anhedonia (DARS; p=0.008) and apathy (AES-S; p<0.001), and improvements were maintained through the six-month open-label period.

    • In an exploratory analysis included in the publication, an MDD diagnosis was significantly associated with greater SHAPS improvement at week 9 relative to dysthymia (p=0.038).

    • In an additional analysis of the trial data not included in the publication, the MDD subgroup showed a larger effect on SHAPS at week 9 (Hedges’ g=0.99) and a larger effect on the Hamilton Depression Rating Scale (HDRS-6) (Hedges’ g=0.64).

    • Consistent with prior studies, adverse events were common in the pramipexole arm despite slow titration, including nausea in approximately 60% of participants — the dose-limiting tolerability constraint that the ALTO-207 fixed-dose combination is designed to address.

  • These findings are consistent with the broader body of evidence supporting ALTO-207, including the PAX-D study conducted by the University of Oxford and published in The Lancet Psychiatry (Cohen’s d=0.87 versus placebo at 12 weeks in TRD) and a meta-analysis of pramipexole in depression (Hedges’ g=0.64, p<0.001).

  • The broad development program for ALTO-207, collectively the PACE program (Pramipexole-ondansetron Assessment of Clinical Efficacy in depression), remains on track across three large, well-controlled clinical trials;

    • PACE-1 Trial (Phase 2b adjunctive TRD trial): Enrollment in the ongoing, potentially registrational, Phase 2b trial of ALTO-207 as an adjunctive treatment in approximately 178 adults with TRD is on track with topline data expected in 2H 2027. MADRS is the primary endpoint in the trial, which is aligned with FDA standards in depression and supports the potential for the trial to contribute to a future registrational package alongside the planned Phase 3 trials.
    • PACE-2 Trial (Phase 3 adjunctive TRD trial): Alto remains on track to initiate its Phase 3 trial of ALTO-207 as adjunctive treatment in TRD by early 2027, following alignment with the FDA on the planned trial design. The Phase 3 trial is designed to run in parallel with the ongoing Phase 2b trial rather than await its topline data, an approach Alto believes can meaningfully accelerate the path to a potential NDA submission.
    • PACE-3 Trial (Phase 3 monotherapy TRD trial): In July 2026, Alto announced plans to accelerate and expand the clinical development of ALTO-207, including an additional planned Phase 3 trial evaluating ALTO-207 as monotherapy in TRD. The Company believes a monotherapy dataset, alongside the planned adjunctive Phase 3 trial, could support a broader label and expand the addressable population for ALTO-207 if approved. Alto expects to initiate this trial in the second half of 2027 pending alignment with the FDA.
  • Alto’s patent estate covering ALTO-207 includes multiple method-of-treatment patents protecting the use of ondansetron to mitigate pramipexole-related side effects to enable higher pramipexole dosing in the treatment of depression. Together with the Company’s broader estate of issued and pending patents, Alto expects patent coverage of ALTO-207 through at least the mid-2040s.

ALTO-300 and ALTO-100: Phase 2b trials on track

  • Enrollment remains ongoing in the Phase 2b trials of ALTO-300 in MDD and ALTO-100 in bipolar depression (BPD), conducted under the enhanced eligibility review and patient data quality procedures the Company implemented earlier this year, which continue to perform as intended.

  • Topline data remain expected in 1H 2027 for the ALTO-300 Phase 2b MDD trial and mid-2027 for the ALTO-100 Phase 2b BPD trial.

Corporate Highlights

  • In July 2026, Alto completed an underwritten registered direct offering of 3,776,436 shares of common stock at $26.48 per share, for gross proceeds of approximately $100.0 million and net proceeds of approximately $94.6 million. The Company intends to use the proceeds, together with existing cash, to accelerate and expand the clinical development of ALTO-207, including the additional planned Phase 3 monotherapy trial in TRD, and for general working capital purposes.

  • In June 2026, Alto was added to the Russell 2000® Index and the broad-market Russell 3000® Index, effective June 29, 2026, as part of the 2026 Russell US Indexes reconstitution.

  • In May 2026, Alto appointed Andrew Miller, Ph.D., founder of Karuna Therapeutics, to its Board of Directors. During his tenure, Dr. Miller was CEO, COO, and led research and development at Karuna through its acquisition by Bristol Myers Squibb, and brings extensive neuropsychiatric drug development and company-building experience to Alto.

Expected Upcoming Milestones

  • Early 2027 — ALTO-207 PACE-2 (Phase 3 adjunctive TRD) trial initiation

  • 1H 2027 — ALTO-300 Phase 2b MDD trial topline data

  • Mid-2027 — ALTO-100 Phase 2b BPD trial topline data

  • 2H 2027 — ALTO-207 PACE-1 (Phase 2b adjunctive TRD) trial topline data

  • 2H 2027 — ALTO-207 PACE-3 (Phase 3 monotherapy TRD) trial initiation

Second Quarter 2026 Financial Highlights

Cash Position: As of June 30, 2026, the Company had cash, cash equivalents, and restricted cash of approximately $244.2 million, compared to approximately $177.0 million as of December 31, 2025. Giving effect to the net proceeds of the July 2026 offering, the Company’s pro forma cash position following the offering was approximately $338 million.

R&D Expenses: Research and development expenses for the quarter ended June 30, 2026, were $22.1 million, as compared to $13.1 million for the same period in 2025.

G&A Expenses: General and administrative expenses for the quarter ended June 30, 2026, were $7.0 million, as compared to $5.6 million for the same period in 2025.

Net Loss: The Company incurred a net loss of $27.6 million for the quarter ended June 30, 2026, as compared to a net loss of $17.7 million for the same period in 2025.

About Alto Neuroscience

Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto’s Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto’s clinical-stage pipeline includes novel drug candidates in treatment-resistant depression, major depressive disorder, bipolar depression, schizophrenia, and other mental health conditions. For more information, visit www.altoneuroscience.com or follow Alto on X.

Forward-Looking Statements

This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “look forward,” “may,” “on track,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding Alto’s expectations with regard to the potential benefits, activity, effectiveness and safety of its product candidates and Precision Psychiatry Platform (“Platform”); statements regarding patient compliance and the effectiveness of Alto’s clinical trial execution measures, including its eligibility review and patient and data quality procedures, and the impact of those measures on patient and data quality and the timing of trial readouts; statements regarding Alto’s expectations for the design, timing, and results of its Phase 2b and planned Phase 3 trials of ALTO-207; Alto’s expectations with regard to the design and results of its research and development programs and clinical trials, including the timing of enrollment and the timing and availability of data from such trials; Alto’s clinical and regulatory development plans for its product candidates, including the timing or likelihood of regulatory filings and approvals for its product candidates and regulatory alignment; Alto’s business strategy, financial position, including anticipated cash runway, and the sufficiency of its financial resources to fund its operations through expected milestones; and other statements that are not historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation, progress and completion of clinical trials and clinical development of Alto’s product candidates; the risk that Alto may not realize the intended benefits of its Platform or its eligibility review and patient and data quality procedures; availability and timing of results from clinical trials; whether initial or interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; the risk that clinical trials may have unsatisfactory outcomes; the risk that Alto’s projections regarding its financial position and expected cash runway are inaccurate or that its conduct of its business requires more cash than anticipated; and other important factors, any of which could cause Alto’s actual results to differ from those contained in the forward-looking statements, which are described in greater detail in Alto’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and other filings Alto may make with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alto expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as required by law.

Availability of Information on Alto’s Website

Alto routinely uses its investor relations website to post presentations to investors and other important information, including information that may be material. Accordingly, Alto encourages investors and others interested in Alto to review the information it makes public on its investor relations website.

 

ALTO NEUROSCIENCE, INC.

Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except per share amounts)

(unaudited)

 

 

 

 

Three months ended

June 30,

Six months ended

June 30,

 

 

2026

 

 

 

2025

 

 

2026

 

 

 

2025

 

Operating expenses:

 

 

 

 

 

 

Research and development

$

22,108

 

 

$

13,124

 

$

42,402

 

 

$

23,098

 

General and administrative

 

7,021

 

 

 

5,558

 

 

13,865

 

 

 

11,260

 

Total operating expenses

 

29,129

 

 

 

18,682

 

 

56,267

 

 

 

34,358

 

Loss from operations

 

(29,129

)

 

 

(18,682

)

 

(56,267

)

 

 

(34,358

)

Other income (expense):

 

 

 

 

 

 

Interest income

 

2,112

 

 

 

1,683

 

 

3,673

 

 

 

3,510

 

Interest expense

 

(491

)

 

 

(646

)

 

(1,036

)

 

 

(1,244

)

Loss on debt extinguishment

 

 

 

 

 

 

 

 

 

(681

)

Other, net

 

(130

)

 

 

(61

)

 

(245

)

 

 

(102

)

Total other income, net

 

1,491

 

 

 

976

 

 

2,392

 

 

 

1,483

 

Net loss

$

(27,638

)

 

$

(17,706

)

$

(53,875

)

 

$

(32,875

)

Other comprehensive income (loss):

 

 

 

 

 

 

Change in fair value attributable to instrument specific credit risk

 

 

 

 

22

 

 

7

 

 

 

156

 

Foreign currency translation

 

4

 

 

 

(5

)

 

(12

)

 

 

(24

)

Total other comprehensive income (loss)

$

4

 

 

$

17

 

$

(5

)

 

$

132

 

Comprehensive loss

$

(27,634

)

 

$

(17,689

)

$

(53,880

)

 

$

(32,743

)

Net loss per share attributable to common stockholders, basic and diluted

$

(0.65

)

 

$

(0.65

)

$

(1.34

)

 

$

(1.21

)

Weighted-average number of common shares outstanding, basic and diluted

 

42,813

 

 

 

27,072

 

 

40,179

 

 

 

27,061

 

 

ALTO NEUROSCIENCE, INC.

Selected Condensed Consolidated Balance Sheet Data

(in thousands)

(unaudited)

 

 

June 30,

 

December 31,

 

 

2026

 

 

 

2025

 

Cash, cash equivalents, and restricted cash

$

244,233

 

 

$

176,984

 

Total assets

 

254,066

 

 

 

184,689

 

Total liabilities

 

34,817

 

 

 

33,547

 

Accumulated deficit

 

(255,509

)

 

 

(201,634

)

 

Investor & Media Contact:

Nick Smith

[email protected]

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Mental Health Health Neurology Clinical Trials Pharmaceutical Biotechnology

MEDIA:

Logo
Logo

Mannatech Reports Financial Results for Second Quarter 2026

FLOWER MOUND, Texas, Aug. 12, 2026 (GLOBE NEWSWIRE) — Mannatech, Incorporated (NASDAQ: MTEX), (“Mannatech” or “Company”), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its second quarter of 2026.


Second Quarter Results

  • Net sales for the three months ended June 30, 2026 were $26.7 million, an increase of $1.0 million, as compared to the same period in 2025. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales increased $1.3 million, or 5.1%, and foreign exchange caused a $0.3 million decrease in GAAP net sales as compared to the same period in 2025.
  • Gross profit as a percentage of net sales increased to 76.9% for the three months ended June 30, 2026, as compared to 73.6% for the same period in 2025.
  • For the three months ended June 30, 2026, selling and administrative expenses decreased by $1.8 million, or 16.7%, to $9.0 million, as compared to the same period in 2025. Selling and administrative expenses, as a percentage of net sales, for the three months ended June 30, 2026 decreased to 33.7% from 42.0% for the same period in 2025.
  • Income from operations was $1.0 million for the three months ended June 30, 2026 as compared to a loss from operations of $1.4 million in the same period in 2025.
  • Income tax expense was $0.2 million for the three months ended June 30, 2026 as compared to less than $0.1 million for the same period in 2025.
  • Net income was $1.0 million for the three months ended June 30, 2026, or $0.53 per diluted share, as compared to a net loss of $4.3 million, or $2.27 per diluted share for the three months ended June 30, 2025.
  • As of June 30, 2026, the Company’s cash and cash equivalents decreased 2.4%, or $0.2 million, to $6.0 million from $6.2 million as of December 31, 2025.
  • The approximate number of new and continuing independent associate and preferred customer positions held by individuals in Mannatech’s network and associated with purchases of its products as of June 30, 2026 was approximately 116,000, as compared to 125,000 in the same period in 2025. Recruiting new associates and preferred customers increased 33.3% in the second quarter of 2026 as compared to the second quarter of 2025.


Management’s Statement

Changes in current trade policies, including with respect to tariffs, could affect our cost structure and profitability. While we take steps to mitigate or avoid these increased costs and disruptions, our ability to do so may be limited by operational and supply chain constraints and uncertainties, especially in the short term.


Non-GAAP Financial Measures

In addition to results presented in accordance with GAAP, this press release and related tables include certain non-GAAP financial measures, including a presentation of Constant dollar measures. The company discloses operating results that have been adjusted to exclude the impact of changes due to the translation of foreign currencies into U.S. dollars, including changes in: Net Sales, Gross Profit, and Loss from Operations.

The Company believes that these non-GAAP financial measures provide useful information to investors because they are an indicator of the strength and performance of ongoing business operations. The constant currency figures are financial measures used by management to provide investors with an additional perspective on trends. Although management believes the non-GAAP financial measures enhance investors’ understanding of their business and performance, these non-GAAP financial measures should not be considered an exclusive alternative to accompanying GAAP financial measures. Please see the accompanying table entitled “Non-GAAP Financial Measures” for a reconciliation of these non-GAAP financial measures.


Safe Harbor statement

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as “may,” “will,” “should,” “hope,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “approximates,” “predicts,” “projects,” “potential,” and “continues” or other similar words or the negative of such terminology. Similarly, descriptions of Mannatech’s objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Mannatech believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties, and other factors. Some of these factors include, among others, Mannatech’s inability to attract and retain associates and members, increases in competition, litigation, regulatory changes, and its planned growth into new international markets. Although Mannatech believes that the expectations, statements, and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.

^ Mannatech operates in China under a cross-border e-commerce platform that is separate from its network marketing model.

Individuals interested in Mannatech’s products or in exploring its business opportunity can learn more at Mannatech.com.

Contact Information:

Erin K. Barta
General Counsel and Corporate Secretary
214-724-3378
[email protected]
www.mannatech.com

MANNATECH, INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS –(UNAUDITED)

(in thousands, except share and per share information)


           
  June 30, 2026     December 31, 2025  
ASSETS              
Cash and cash equivalents $ 6,034     $ 6,185  
Restricted cash   218       550  
Accounts receivable, net of allowance of $308 and $756   137       1  
Income tax receivable   386       736  
Inventories, net   9,593       10,123  
Prepaid expenses and other current assets   2,009       1,701  
Deferred commissions   1,035       1,280  
Total current assets   19,412       20,576  
Property and equipment, net   2,749       3,140  
Operating lease right-of-use assets   2,515       3,292  
Other assets   2,570       2,751  
Deferred tax assets, net          
Long-term restricted cash   223       234  
Total assets $ 27,469     $ 29,993  
LIABILITIES AND SHAREHOLDERS’ DEFICIT              
Commissions and incentives payable $ 5,832     $ 7,118  
Accrued expenses   2,939       3,128  
Deferred revenue   1,761       3,086  
Accounts payable   3,671       2,410  
Current portion of operating lease liabilities   1,584       1,671  
Taxes payable   511       1,029  
Current notes payable   266        
Current portion of finance lease liabilities   301       293  
Total current liabilities   16,865       18,735  
Long-term notes payable   2,750       2,750  
Operating lease liabilities, excluding current portion   1,474       2,253  
Other long-term liabilities   1,364       1,340  
Finance lease liabilities, excluding current portion   236       388  
Deferred tax liabilities, net   9,750       9,750  
Total liabilities   32,439       35,216  
               
Commitments and contingencies (Note 8)              
               
Shareholders’ deficit:              
Preferred stock, $0.01 par value, 1,000,000 shares authorized, no shares issued or outstanding          
Common stock, $0.0001 par value, 99,000,000 shares authorized, 2,742,857 shares issued and 1,929,670 shares outstanding as of June 30, 2026 and 2,742,857 shares issued and 1,900,930 shares outstanding as of December 31, 2025          
Additional paid-in capital   32,692       33,032  
Accumulated deficit   (12,059 )     (14,024 )
Accumulated other comprehensive loss   (6,709 )     (4,669 )
Treasury stock, at average cost, 813,187 shares as of June 30, 2026 and 841,927 shares as of December 31, 2025   (18,894 )     (19,562 )
Total shareholders’ deficit   (4,970 )     (5,223 )
Total liabilities and shareholders’ deficit $ 27,469     $ 29,993  

MANNATECH, INCORPORATED AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS – (

UNAUDITED

)

(in thousands, except per share information)
           
  Three Months Ended     Six Months Ended  
  June 30,     June 30,  
  2026     2025     2026     2025  
Net sales $ 26,650     $ 25,679     $ 51,567     $ 52,242  
Cost of sales   6,164       6,778       12,220       13,605  
Gross profit   20,486       18,901       39,347       38,637  
Operating expenses:                              
Commissions and incentives   10,512       9,567       20,270       20,120  
Selling and administrative expenses   8,976       10,777       18,258       20,793  
Total operating expenses   19,488       20,344       38,528       40,913  
Income (loss) from operations   998       (1,443 )     818       (2,276 )
Interest expense, net   (117 )     (102 )     (221 )     (175 )
Other income (expense), net   284       (2,744 )     1,679       (3,162 )
Income (loss) before income taxes   1,165       (4,289 )     2,276       (5,613 )
Income tax expense   (150 )     (23 )     (311 )     (229 )
Net income (loss) $ 1,015     $ (4,312 )   $ 1,965     $ (5,842 )
Income (loss) per common share:                              
Basic $ 0.53     $ (2.27 )   $ 1.02     $ (3.07 )
Diluted $ 0.53     $ (2.27 )   $ 1.02     $ (3.07 )
Weighted-average common shares outstanding:                              
Basic   1,930       1,901       1,930       1,901  
Diluted   1,930       1,901       1,930       1,901  

Net sales by region for the three and six months ended June 30, 2026 and 2025 were as follows (in millions, except percentages):

  Three Months Ended     Six Months Ended  
  June 30,     June 30,  

Region
2026     2025     2026     2025  
Americas $ 8.4       31.5 %   $ 8.3       32.3 %   $ 15.1       29.3 %   $ 17.2       33.0 %
Asia/Pacific   15.9       59.6 %     15.3       59.5 %     31.7       61.4 %     30.7       58.8 %
EMEA   2.4       9.0 %     2.1       8.2 %     4.8       9.3 %     4.3       8.2 %
Total net sales $ 26.7       100.0 %   $ 25.7       100.0 %   $ 51.6       100.0 %   $ 52.2       100.0 %



Non-GAAP Financial Measures (Sales, Gross Profit and Loss from Operations in Constant Dollars)

To supplement its financial results presented in accordance with generally accepted accounting principles in the United States (“GAAP”), Mannatech discloses operating results that have been adjusted to exclude the impact of changes due to the translation of foreign currencies into U.S. dollars, including changes in: Net Sales, Gross Profit, and Income (Loss) from Operations. It refers to these adjusted financial measures as Constant dollar items, which are non-GAAP financial measures. The company believes these measures provide investors with an additional perspective on trends. To exclude the impact of changes due to the translation of foreign currencies into U.S. dollars, it calculates current year results and prior year results at a constant exchange rate, which is the prior year’s rate. Currency impact is determined as the difference between the actual GAAP results and the recalculated results for the current year at the Constant dollar rates.

The tables below reconcile second quarter and year-to-date 2026 Constant dollar net sales, gross profit and income (loss) from operations to GAAP net sales, gross profit and income (loss) from operations. (in millions, except percentages):

Three-month period ended June 30, 2026     June 30, 2025     Constant $ Change  
  GAAP             Non-GAAP     GAAP                  
  Measure:     Translation     Measure:     Measure:                  
  Total $     Adjustment     Constant $     Total $     Dollar     Percent  
Net sales $ 26.7     $ 0.3     $ 27.0     $ 25.7     $ 1.3       5.1 %
Gross profit $ 20.5     $ 0.3     $ 20.8     $ 18.9     $ 1.9       10.1 %
Income (loss) from operations $ 1.0     $ 0.0     $ 1.0     $ (1.4 )   $ 2.4       (171.4 )%

Six-month period ended June 30, 2026     June 30, 2025     Constant $ Change  
  GAAP             Non-GAAP     GAAP                  
  Measure:     Translation     Measure:     Measure:                  
  Total $     Adjustment     Constant $     Total $     Dollar     Percent  
Net sales $ 51.6     $ (0.2 )   $ 51.4     $ 52.2     $ (0.8 )     (1.5 )%
Gross profit $ 39.3     $ (0.1 )   $ 39.2     $ 38.6     $ 0.6       1.6 %
Income (loss) from operations $ 0.8     $ (0.1 )   $ 0.7     $ (2.3 )   $ 3.0       (130.4 )%



Kura Oncology Reports Second Quarter 2026 Financial Results

– KOMZIFTI

®

(ziftomenib) generated $9.1 million in net product revenue, up 57% over 1Q, and approximately 115 new patient starts, up 35% over 1Q –

– KOMZIFTI® achieved majority share of new patient starts in R/R NPM1-m AML menin inhibitor class, establishing leadership after just two full quarters of launch –


Long-term, frontline AML data presented at EHA 2026 support potential for ziftomenib to transform standard of care and a $7 billion TAM

– Clinical updates support darlifarnib’s potential to enhance targeted therapies in RCC and KRAS-mutated tumors –

– $519.0 million in cash, cash equivalents and short-term investments, plus $180 million in anticipated collaboration payments –

– Management to host webcast and conference call today at 4:30 p.m. ET / 1:30 p.m. PT –

SAN DIEGO, Aug. 12, 2026 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for cancer, today reported second quarter 2026 financial results and provided a corporate update.

“In only its second full quarter of launch, KOMZIFTI established early leadership in relapsed or refractory NPM1-mutant AML, achieving a majority share of new patient starts in the menin inhibitor class,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. “Increasing physician preference for KOMZIFTI, combined with outstanding commercial execution and encouraging frontline data, establish a strong foundation for ziftomenib as a potential market leader throughout the AML treatment continuum. In parallel, darlifarnib is emerging as a differentiated precision combination platform across multiple targeted therapies in major solid tumor indications. Together, these programs position Kura to build long-term value while advancing innovative therapies for patients with significant unmet need.”

Recent Developments

KOMZIFTI Commercial Launch

Commercial highlights for the quarter included:

  • $9.1 million in net product revenue, a 57% increase from 1Q 2026

  • Approximately 115 new patient starts (NPS), a 35% increase from 1Q 2026

  • More than 250 total prescriptions (TRx) in 2Q 2026, including repeat prescriptions, a 59% increase from 1Q 2026

  • In its second full quarter on the market, KOMZIFTI achieved a majority share of new patient starts in the R/R NPM1-m AML menin inhibitor class

New patient starts are a key indicator of physician preference, future prescription growth, and overall market leadership. Additional indicators of KOMZIFTI’s commercial momentum included broader adoption across academic and community treatment centers, increasing repeat prescribing, and physician-directed use of KOMZIFTI in combination with established standards of care.

Advancing Ziftomenib Across the Broader AML Treatment Landscape

  • EHA 2026

    Long-term KOMET-007 data demonstrated high and durable clinical activity with 600 mg ziftomenib plus intensive chemotherapy (7+3) in 99 patients with newly diagnosed NPM1-m or KMT2A-r AML, including:

    • CRc rates of 96% and 90%, respectively
    • 12-month OS rates of 94% and 71%, respectively
    • Deep MRD negativity, no new safety signals, and median overall survival not reached in either molecular subgroup

  • Blood

    Publication (June 2026)

    Updated KOMET-007 results demonstrated deep and durable responses with 600 mg ziftomenib plus venetoclax and azacitidine in R/R NPM1-m AML. Venetoclax-naïve patients achieved an 87% ORR and 70% CRc rate, with 75% of composite complete responders achieving central MRD negativity. Median duration of CRc was 9.2 months. Median OS in these patients was not reached after 10.7 months of follow-up. The regimen was generally well tolerated, with low rates of differentiation syndrome and QTc prolongation.

Together, these results support the potential of ziftomenib in combination with standard-of-care regimens, increasing confidence in the ongoing KOMET-017 frontline program.

  • Registrational and Combination Programs

    • Site activation and patient enrollment across KOMET-017 frontline registrational studies for intensive and non-intensive chemotherapy eligible patients ongoing
    • Enrollment in KOMET-008 evaluating ziftomenib plus gilteritinib in patients with R/R FLT3-ITD/NPM1 co-mutated AML continues
    • Enrollment in the KOMET-007 cohort evaluating ziftomenib plus quizartinib and intensive chemotherapy in patients with newly diagnosed FLT3/NPM1 co-mutated AML ongoing

Advancing Darlifarnib as a Precision Combination Platform Across Solid Tumors

  • KRAS

    G12C

    -mutated Solid Tumors (ASCO 2026)

    First-in-human Phase 1 FIT-001 data evaluating darlifarnib plus adagrasib provided clinical proof of mechanism, including tumor shrinkage in 77% of response-evaluable patients and confirmed ORRs of:

    • 67% in pancreatic cancer
    • 50% in non-small cell lung cancer
    • 29% in KRAS inhibitor-naïve colorectal cancer
  • Cabozantinib-naïve Clear Cell Renal Cell Carcinoma (KCRS 2026)

    Updated Phase 1 FIT-001 results demonstrated encouraging and durable clinical activity with darlifarnib plus cabozantinib, with ORRs of up to 50% across dose levels and an mPFS of 13 months.

  • Cabozantinib-exposed Clear Cell Renal Cell Carcinoma (IKCS 2026)

    Phase 1 FIT-001 data demonstrated darlifarnib’s potential to overcome resistance to VEGFR-targeted therapy. Despite prior cabozantinib exposure, patients on the combination of darlifarnib plus cabozantinib, across multiple dose levels of each, achieved a:

    • 44% ORR
    • 94% disease control rate (DCR)
    • Tumor shrinkage in 75% of patients

Collectively, these data continue to support darlifarnib’s potential as a precision combination platform capable of enhancing multiple targeted therapy classes while creating opportunities for future development opportunities, potential strategic collaborations, and multiple registrational paths.

  • FIT-001 Phase 1b Dose Expansion

    Enrollment continues in the global, randomized FIT-001 Phase 1b study evaluating darlifarnib plus cabozantinib versus cabozantinib alone to establish the recommended Phase 3 dose in patients with cabozantinib-naïve ccRCC.

Anticipated Milestones: Commercial and Development Priorities

Kura expects multiple commercial and clinical catalysts over the next 12 to 18 months.

KOMZIFTI 2026 Commercial Execution

  • Expand physician adoption across academic and community treatment centers
  • Increase repeat prescribing and broaden physician adoption
  • Deliver sustained quarter-over-quarter growth
  • Strengthen leadership within R/R NPM1-m AML menin inhibitor market

Building on Emerging Leadership Across the AML Treatment Continuum

Kura’s strategy is to build on KOMZIFTI’s early commercial success by moving ziftomenib into earlier lines of therapy, combining it with multiple standards of care and expanding its use across genetically defined AML populations.

Key near-term milestones include anticipated presentation of:

  • Updated long-term KOMET-007 Phase 1b data evaluating ziftomenib with venetoclax and azacitidine in newly diagnosed, intensive chemotherapy-ineligible NPM1-m AML patients, including durability, survival, and MRD outcomes – 2H 2026
  • Initial data from the KOMET-007 Phase 1b study evaluating ziftomenib with 7+3 intensive chemotherapy and quizartinib in patients with newly diagnosed NPM1-m/FLT3-ITD AML – 2H 2026
  • Initial KOMET-008 data evaluating ziftomenib with gilteritinib in patients with R/R NPM1-m/FLT3-m AML, including activity in patients previously treated with FLT3 inhibitors – 2H 2026
  • An exploratory analysis from the KOMET-001 study evaluating ziftomenib monotherapy activity in molecularly defined, MEIS1-associated AML subtypes beyond NPM1-m and KMT2A-r disease – 2H 2026

Ziftomenib and Menin Inhibition – Expansion Beyond AML

  • Continue enrollment of KOMET-015 study evaluating ziftomenib plus imatinib in patients with gastrointestinal stromal tumors
  • Progress preclinical development of next-generation menin inhibitor for use in other solid tumors

KO-7246 (Next-Generation Menin Inhibitor)

  • Advance KO-7246, a next-generation menin inhibitor specifically designed for use in diabetes and cardiometabolic disease, into IND-enabling studies
  • Present additional scientific data characterizing menin inhibitors in preclinical models of diabetes

Darlifarnib – Precision Combination Platform in Solid Tumors

  • Complete enrollment in the randomized FIT-001 Phase 1b study evaluating darlifarnib plus cabozantinib in cabozantinib-naïve ccRCC in 1H 2027 and report initial clinical data in 2H 2027
  • Initiate a platform study of darlifarnib plus daraxonrasib in patients with KRAS-mutant 2L+ PDAC in 1H 2027
  • Advance darlifarnib as a precision combination platform across additional targeted therapy classes

Second Quarter 2026 Financial Results

  • Net product revenue: $9.1 million, compared to none for 2Q 2025
  • Collaboration revenue: $11.8 million, compared to $15.3 million for 2Q 2025
  • R&D expenses: $61.9 million, compared to $62.8 million for 2Q 2025
  • SG&A expenses: $31.8 million, compared to $25.2 million for 2Q 2025
  • Net loss: $68.3 million, compared to $66.1 million for 2Q 2025. Net loss includes $8.2 million in non-cash, share-based compensation expense compared to $6.9 million for the same period in 2025.

As of June 30, 2026, Kura had $519.0 million in cash, cash equivalents and short-term investments, compared to $667.2 million as of December 31, 2025.   Combined with $180 million in anticipated collaboration payments from Kyowa Kirin, the Company believes its current cash resources will be sufficient to fund the ziftomenib AML program through the topline results from the first pivotal Phase 3 KOMET-017 trial, anticipated in 2028.

Conference Call and Webcast

Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT today, August 12, 2026, to discuss financial results and to provide a corporate update. A live webcast and archived replay of the event will be available on the Investors section of the Company’s website at www.kuraoncology.com.

About Kura Oncology

Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website and follow us on X and LinkedIn.

Forward-Looking Statements

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the commercial potential of KOMZIFTI; physician preference for KOMZIFTI; Kura’s research, preclinical and clinical development activities; plans and projected timelines for ziftomenib, darlifarnib, KO-7246, and other preclinical assets; ziftomenib’s potential to transform the standard of care for AML and to serve as a foundational therapy and market leader across the AML treatment continuum; the market opportunity for ziftomenib; darlifarnib’s potential to serve as a precision combination platform and enhance clinical activity in multiple targeted therapy classes, while creating opportunities for future development, potential strategic collaborations, and multiple registrational paths; the expected timing and presentation of results and data from clinical trials; Kura’s ability to generate long-term value; and Kura’s anticipated cash runway. Factors that may cause actual results to differ materially include risks associated with market competition, market acceptance and commercialization of KOMZIFTI and Kura’s product candidates; risks associated with the conduct of preclinical studies and clinical trials; the risk that Kura may not obtain access to third-party compounds Kura seeks to evaluate in combination with its product candidates; the risk of the FDA not permitting Kura’s planned trials to proceed; the risk that Kura’s product candidates may not receive regulatory approval; the potential for KOMZIFTI or Kura’s product candidates to have unexpected adverse side effects; risks that Kura’s actual future financial and operating results may differ from its expectations or goals; the risk that Kura may not be able to obtain additional financing; the risk that the collaboration with Kyowa Kirin is unsuccessful; and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to the Company’s periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Kura assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Abbreviations

7+3, cytarabine plus daunorubicin; AML, acute myeloid leukemia; ccRCC, clear cell renal cell carcinoma; CRc, composite complete remission; DCR, disease control rate; FLT3, Fms-like tyrosine kinase 3 gene; FLT3-ITD, FMS-like tyrosine kinase 3 internal tandem duplication; G12C, a specific amino-acid substitution; IND, Investigational New Drug application; KMT2A, lysine methyltransferase 2A gene; -m, mutant; MEIS1, Myeloid Ecotropic Viral Integration Site 1; NPM1, nucleophosmin 1 gene; ITD, Internal Random Duplication; ORR, overall response rate; OS, overall survival; PDAC, pancreatic ductal adenocarcinoma; -r, rearranged; KRAS, Kirsten Rat Sarcoma Virus oncogene homolog; mPFS, median progression free survival, MRD, minimal residual disease; QTc, corrected QT interval; R/R, relapsed/refractory; VEGFR, vascular endothelial growth factor receptor

KURA ONCOLOGY, INC.  
Statements of Operations Data  
(unaudited)  
(in thousands, except per share data)  
                         
    Three Months Ended     Six Months Ended  
    June 30,     June 30,  
    2026     2025     2026     2025  
Revenue                        
Product revenue, net   $ 9,122     $     $ 14,888     $  
Collaboration revenue     11,752       15,288       24,251       29,396  
Total revenue     20,874       15,288       39,139       29,396  
Operating expenses                        
Cost of product sales     243             505        
Research and development     61,891       62,785       127,154       118,758  
Selling, general and administrative     31,750       25,169       63,305       48,004  
Total operating expenses     93,884       87,954       190,964       166,762  
Other income, net     4,688       6,544       10,178       14,041  
Income tax expense     5             13       226  
Net loss   $ (68,327 )   $ (66,122 )   $ (141,660 )   $ (123,551 )
Net loss per share, basic and diluted   $ (0.77 )   $ (0.75 )   $ (1.60 )   $ (1.41 )
Weighted average number of shares used in computing net loss per share, basic and diluted     88,855       87,586       88,733       87,501  



KURA ONCOLOGY, INC.  
Balance Sheet Data  
(unaudited)  
(in thousands)  
             
    June 30,     December 31,  
    2026     2025  
Cash, cash equivalents and short-term investments   $ 519,025     $ 667,240  
Working capital     441,246       591,689  
Total assets     587,791       738,363  
Long-term liabilities     421,167       447,254  
Accumulated deficit     (1,315,748 )     (1,174,088 )
Stockholders’ equity     48,431       174,135  



About KOMZIFTI


®

(ziftomenib)

KOMZIFTI (ziftomenib) is an oral menin inhibitor approved for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation who have no satisfactory alternative treatment options.

Ziftomenib is in development for the treatment of frontline and R/R AML harboring NPM1 mutations, KMT2A translocations and FLT3 mutations, with the potential to be combined with approved therapies and benefit a broad spectrum of patients.

IMPORTANT SAFETY INFORMATION FOR KOMZIFTI FROM THE U.S. PRESCRIBING INFORMATION

Boxed WARNING: DIFFERENTIATION SYNDROME

Differentiation syndrome, which can be fatal, has occurred with KOMZIFTI. Signs and symptoms may include fever, joint pain, hypotension, hypoxia, dyspnea, rapid weight gain or peripheral edema, pleural or pericardial effusions, pulmonary infiltrates, acute kidney injury, and rashes. If differentiation syndrome is suspected, interrupt KOMZIFTI, and initiate oral or intravenous corticosteroids with hemodynamic and laboratory monitoring until symptom resolution; resume KOMZIFTI upon symptom improvement.

WARNINGS AND PRECAUTIONS

Differentiation Syndrome

KOMZIFTI can cause fatal or life-threatening differentiation syndrome (DS). DS is associated with rapid proliferation and differentiation of myeloid cells. Symptoms of DS, including those seen in patients treated with KOMZIFTI, may include fever, hypoxia, joint pain, hypotension, dyspnea, rapid weight gain or peripheral edema, pleural or pericardial effusions, acute kidney injury, and rashes.

In the clinical trial, DS occurred in 29 (26%) of 112 patients with R/R AML with an NPM1 mutation who were treated with KOMZIFTI at the recommended dosage. DS was Grade 3 in 13% and fatal in two patients. In broader evaluation of all patients with any genetic form of AML treated with KOMZIFTI monotherapy in clinical trials, DS occurred in 25% of patients. Four fatal cases of DS occurred out of 39 patients with KMT2A-rearranged AML treated with KOMZIFTI. KOMZIFTI is not approved for use in patients with KMT2A-rearranged AML.

In the 112 patients with an NPM1 mutation, DS was observed with and without concomitant hyperleukocytosis, in as early as 3 days and up to 46 days after KOMZIFTI initiation. The median time to onset was 15 days. Two patients experienced more than one DS event. Treatment was interrupted and resumed in 15 (13%) patients, while it was permanently discontinued in 2 (2%) patients.

Prior to starting treatment with KOMZIFTI, reduce the WBC counts to less than 25 x 10⁹/L. If DS is suspected, interrupt KOMZIFTI, initiate oral or intravenous corticosteroids (e.g., dexamethasone 10 mg every 12 hours) for a minimum of 3 days with hemodynamic and laboratory monitoring. Resume treatment with KOMZIFTI at the same dose level when signs and symptoms improve and are Grade 2 or lower. Taper corticosteroids over a minimum of 3 days after adequate control or resolution of symptoms. Symptoms of DS may recur with premature discontinuation of corticosteroid treatment.

QTc Interval Prolongation

KOMZIFTI can cause QTc interval prolongation. In the clinical trial, QTc interval prolongation was reported as an adverse reaction in 12% of 112 patients treated with KOMZIFTI at the recommended dosage for R/R AML with an NPM1 mutation. QTc interval prolongation was Grade 3 in 8% of patients. The heart-rate corrected QT interval (using Fridericia’s method) (QTcF) was greater than 500 msec in 9% of patients, and the increase from baseline QTcF was greater than 60 msec in 12% of patients. KOMZIFTI dose reduction was required for 1% of patients due to QTc interval prolongation. QTc prolongation occurred in 14% of the 42 patients less than 65 years of age and in 10% of the 70 patients 65 years of age or older.

Correct electrolyte abnormalities, including hypokalemia and hypomagnesemia, prior to treatment with KOMZIFTI. Perform an ECG prior to initiation of treatment with KOMZIFTI, and do not initiate KOMZIFTI in patients with QTcF > 480 msec. Perform an ECG at least once weekly for the first four weeks on treatment, and at least monthly thereafter. Interrupt KOMZIFTI if the QTc interval is > 500 ms or the change from baseline is > 60 ms (Grade 3). In patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval, more frequent ECG monitoring may be necessary. Concomitant use of KOMZIFTI with drugs known to prolong the QTc interval may increase the risk of QTc interval prolongation, result in a greater increase in the QTc interval and adverse reactions associated with QTc interval prolongation, including Torsades de Pointes, other serious arrhythmias, and sudden death.

Embryo-Fetal Toxicity

Based on findings in animals and its mechanism of action, KOMZIFTI can cause embryo-fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with KOMZIFTI and for 6 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with KOMZIFTI and for 3 months after the last dose.

ADVERSE REACTIONS

Fatal adverse reactions occurred in 4 (4%) patients who received KOMZIFTI, including 2 with differentiation syndrome, 1 with infection, and 1 with sudden death. Serious adverse reactions were reported in 79% of patients who received KOMZIFTI. Serious adverse reactions occurring in ≥ 5% of patients included infection without an identified pathogen (29%), febrile neutropenia (18%), bacterial infection (16%), differentiation syndrome (16%), and dyspnea (6%).

Dosage interruption of KOMZIFTI due to an adverse reaction occurred in 54% of patients. Adverse reactions that required dose interruption in ≥ 2% of patients included infection without an identified pathogen (15%), differentiation syndrome (13%), febrile neutropenia (5%), pyrexia (4%), electrocardiogram QT prolonged (4%), leukocytosis (4%), bacterial infection (3%), cardiac failure (2%), cholecystitis (2%), diarrhea (2%), pruritus (2%), and thrombosis (2%). Dose reduction of KOMZIFTI due to an adverse reaction occurred in 4% of patients. Permanent discontinuation of KOMZIFTI due to an adverse reaction occurred in 21% of patients. Adverse reactions that required permanent discontinuation of KOMZIFTI in ≥ 2% of patients were infection without an identified pathogen (8%), bacterial infection (4%), cardiac arrest (2%), and differentiation syndrome (2%).

Most common (≥ 20%) adverse reactions, including laboratory abnormalities, were aspartate aminotransferase increased (53%), infection without an identified pathogen (52%), potassium decreased (52%), albumin decreased (51%), alanine aminotransferase increased (50%), sodium decreased (49%), creatinine increased (45%), alkaline phosphatase increased (41%), hemorrhage (38%), diarrhea (36%), nausea (35%), fatigue (34%), edema (30%), bacterial infection (28%), musculoskeletal pain (28%), bilirubin increased (27%), potassium increased (26%), differentiation syndrome (26%), pruritus (23%), febrile neutropenia (22%), and transaminases increased (21%).

DRUG INTERACTIONS

Drug interactions may occur when KOMZIFTI is concomitantly used with:

  • Strong or Moderate CYP3A4 Inhibitors: Monitor patients more frequently for KOMZIFTI-associated adverse reactions.
  • Strong or Moderate CYP3A4 Inducers: Avoid concomitant use of KOMZIFTI.
  • Gastric Acid Reducing Agents: Avoid concomitant use of KOMZIFTI with proton pump inhibitors (PPIs), H2 receptor antagonists (H2RAs), or locally acting antacids. If concomitant use with H2RAs or locally acting antacids cannot be avoided, modify KOMZIFTI administration time.
    • Take KOMZIFTI 2 hours before or 10 hours after administration of an H2 receptor antagonist.
    • Take KOMZIFTI 2 hours before or 2 hours after administration of a locally acting antacid.
  • Drugs that Prolong the QTc Interval: Avoid concomitant use of KOMZIFTI. If concomitant use cannot be avoided, obtain ECGs when initiating, during concomitant use, and as clinically indicated. Interrupt KOMZIFTI if the QTc interval is > 500 ms or the change from baseline is > 60 ms.

USE IN SPECIFIC POPULATIONS

Pregnancy: Based on findings in animals and its mechanism of action, KOMZIFTI can cause embryo-fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Verify pregnancy status in females of reproductive potential prior to starting KOMZIFTI.

Lactation: Because of the potential for adverse reactions in the breastfed child, advise women not to breastfeed during treatment with KOMZIFTI and for 2 weeks after the last dose.

Infertility: Based on findings in animals, KOMZIFTI may impair fertility in females and males of reproductive potential.

Please see full Prescribing Information, including Boxed WARNING.

Contacts

Investors and media:
Greg Mann
858-987-4046
[email protected]



Omeros Corporation Reports Second Quarter 2026 Financial Results

Omeros Corporation Reports Second Quarter 2026 Financial Results

– Conference Call Today at 4:30 p.m. ET

SEATTLE–(BUSINESS WIRE)–
Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2026, which include:

Second Quarter and Recent Highlights

  • YARTEMLEA®, the first and only approved treatment for stem cell transplant-associated thrombotic microangiopathy (TA-TMA), an often-lethal complication of stem cell transplantation, generated gross revenues of $32.2 million in the second quarter of 2026, an increase of 190% from $11.1 million in the first quarter. Net revenue was $28.5 million, reflecting gross-to-net adjustments of approximately 11.5%, compared with $9.9 million and 11.0%, respectively, in the first quarter.

  • Net income for the second quarter of 2026 was $13.2 million, or $0.18 per share, compared to net income of $56.1 million, or $0.78 per share for the first quarter of 2026.

  • Results for the second and first quarters of 2026 included non-cash gains of $11.5 million and $73.1 million, respectively, primarily related to the mark-to-market adjustment of the embedded derivative associated with our unsecured convertible notes due 2029 (the “2029 Notes”). Excluding these non-cash gains, non-GAAP adjusted net income for the second quarter of 2026 was $1.8 million, or $0.02 per share, compared with a non-GAAP adjusted net loss of $17.1 million, or $0.24 per share, for the first quarter.

  • At June 30, 2026, we had $132.0 million of cash and short-term investments. For the three months ended June 30, 2026, company-wide net cash provided by operations was $4.1 million.

  • In July 2026, we completed the repurchase of $30.5 million aggregate principal amount of our 2029 Notes for a total purchase price of $60.2 million, reducing the outstanding principal amount to approximately $40.3 million. The transactions also reduced the aggregate number of shares issuable upon conversion of the 2029 Notes from approximately 11.4 million to 6.5 million and eliminated $8.6 million in future interest payments.

  • During the three and six months ended June 30, 2026, we repurchased and retired approximately 0.5 million and 0.8 million shares of common stock, respectively, at an average cost of $11.70 per share, respectively, for aggregate purchase prices of $5.7 million and $9.9 million, respectively.

  • In June, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a negative opinion on our marketing authorization application (MAA) for narsoplimab in TA-TMA. We believe the clinical evidence supports approval and have requested re-examination. As part of the re-examination procedure, an Ad Hoc Expert Group (AHEG), expected to comprise external scientific and clinical experts in hematology and stem cell transplantation, will review the evidence and address questions central to CHMP’s assessment. We continue to make YARTEMLEA available to transplant physicians and their patients in Europe through our expanded access program, prioritizing children with TA-TMA.

“We are very pleased with the strong momentum and growing market acceptance in the first full quarter of YARTEMLEA’s commercial launch,” said Gregory A. Demopulos, M.D., Omeros’ Chairman and Chief Executive Officer. “Equally gratifying are the consistent reports from transplant physicians nationwide describing responses to YARTEMLEA in their adult and pediatric patients, including those who had not responded to prior off-label C5 inhibitor administration. YARTEMLEA is saving lives and, with FDA approval, is now broadly accessible in the U.S. Substantial second-quarter YARTEMLEA revenues have enabled us to continue strengthening our capital structure. We repurchased an additional 489,000 shares of common stock in the open market and reduced the outstanding principal amount of our 2029 convertible notes by 43%, eliminating nearly $9 million in future cash interest payments and approximately 5 million additional shares of potential dilution. At the same time, our work with Novo Nordisk on the MASP-3 inhibitor zaltenibart remained on track toward Phase 3 trial initiation, while our complement, addiction, oncology, and infectious disease programs continued advancing. Collectively, these programs position Omeros for a broad range of value-driving milestones over the next 18 months.”

Recent Developments

  • YARTEMLEA and our broader MASP-2 inhibitor platform

    • On July 1, 2026, the permanent Healthcare Common Procedure Coding System J-code specific for YARTEMLEA became effective. Also in July, the Centers for Medicare & Medicaid Services (CMS) granted New Technology Add-on Payment (NTAP) status to YARTEMLEA, effective October 1, 2026. The NTAP designation provides eligible hospitals with additional Medicare reimbursement for inpatient cases involving YARTEMLEA and is expected to support patient access to this first-in-class treatment for TA-TMA.

    • We are assessing further development opportunities for YARTEMLEA across indications involving endothelial injury, lectin pathway activation, or thrombo-inflammation, including solid organ transplant-related TMA, chemotherapy-induced TMA, acute respiratory distress syndrome (ARDS), sickle cell disease, acute kidney injury, delayed graft function, and stem cell transplant-related endothelial syndromes beyond TA-TMA, including diffuse alveolar hemorrhage, capillary leak syndrome, graft-versus-host disease, and sinusoidal obstruction syndrome.

    • By year-end 2026, we expect enrollment to begin in two investigator-sponsored and Omeros-supported studies, one evaluating YARTEMLEA in hyperinflammatory ARDS, and the other assessing prophylactic YARTEMLEA in pediatric patients with predictably severe TA-TMA.

    • In parallel, we are finalizing the initial indication for a Phase 2 clinical program for OMS1029, our long-acting antibody targeting MASP-2. In our MASP-2 small-molecule inhibitor program, following completion of one ongoing study, we expect to select a drug development candidate.

  • OMS527 for the treatment of addiction — cocaine use disorder program funded by the National Institute on Drug Abuse (“NIDA”)

    • We are developing, at NIDA’s request, our lead orally administered phosphodiesterase 7 (“PDE7”) inhibitor for the treatment of cocaine use disorder. Preclinical studies, designed with NIDA toxicologists, were completed and showed no drug-interaction or safety issues, supporting the scheduled in-patient human study of OMS527 in cocaine users.

    • We are initiating a nonclinical study responsive to FDA’s request for additional nonclinical information prior to beginning the inpatient clinical trial. We expect to be able start enrollment in the inpatient clinical trial by year-end 2026.

  • Oncology platform — OncotoX-AML/OMS805

    • We continue to progress development within our OncotoX-AML/OMS805 program targeting acute myeloid leukemia (“AML”), an aggressive and highly fatal bone marrow and blood cancer.

    • A first-in-human Phase 1b clinical trial evaluating OMS805, the lead drug development candidate in our OncotoX-AML program, is targeted to begin in late 2027. IND-enabling studies are underway, and we have entered into an agreement with a leading contract biologics manufacturer for process development and initial clinical supply of OMS805 drug substance.

    • Across tumor-bearing animal models and in vitro human AML cell-line studies, OMS805 demonstrated efficacy superior to current AML standards of care. This efficacy was independent of AML-related genetic mutations, including TP53, NPM1, KMT2A, and FLT3, collectively found in approximately 90% of AML patients.

    • In February 2026, we announced the successful completion of our initial study in nonhuman primates evaluating the efficacy and safety of OncotoX-AML. Administration of only one course of OncotoX-AML treatment to immunocompetent primates produced the desired pharmacologic response, selectively reducing myeloid progenitor cells by up to 99%. OncotoX-AML was well tolerated. There were no observed safety signals or meaningful changes in blood chemistry values.

  • Targeted Complement Activating Therapy (“T-CAT”) platform

    • Our T-CAT platform is a new class of recombinant antibodies designed to target and directly kill pathogens, including bacteria, fungi, viruses, and parasites. Our T-CAT antibodies are expected to treat drug-resistant organisms without enhancing drug resistance. Our initial focus is on developing T-CAT antibodies against infections caused by multidrug-resistant organisms (“MDROs”), one of the most critical unmet needs in medicine.

    • The first peer-reviewed manuscript describing our T-CAT technology, titled “Engineered Antibodies Bypass Bacterial Immune Evasion to Drive Complement-Mediated Protection Against Lethal Infections,” was published in Science Translational Medicine on June 17, 2026. The manuscript underscores T-CAT’s potential as a next-generation platform with broad applicability across microbial species, including MDROs.

Financial Results

YARTEMLEA gross revenues were $32.2 million during the second quarter of 2026, an increase of $21.1 million, or 190%, from gross revenues of $11.1 million in the first quarter of 2026. Net revenue was $28.5 million, reflecting gross-to-net adjustments of approximately 11.5%, compared with $9.9 million, and gross-to-net adjustments of approximately 11.0% in the first quarter of 2026.

Net income for the second quarter of 2026 was $13.2 million, or $0.18 per share, compared to net income of $56.1 million, or $0.78 per share, for the first quarter of 2026.

Results for the second and first quarters of 2026 included non-cash gains of $11.5 million and $73.1 million, respectively, primarily related to the mark-to-market adjustment of the embedded derivative associated with our 2029 Notes. Excluding these non-cash gains, non-GAAP adjusted net income for the second quarter of 2026 was $1.8 million, or $0.02 per share, compared with a non-GAAP adjusted net loss of $17.1 million, or $0.24 per share, for the first quarter of 2026.

At June 30, 2026, we had $132.0 million of cash and short-term investments. For the three months ended June 30, 2026, company-wide net cash provided by operations was $4.1 million.

On June 17, 2026, we entered into privately negotiated agreements to repurchase $16.0 million aggregate principal amount of 2029 Notes from certain holders. On July 2, 2026, we entered into additional privately negotiated agreements with the same holders to repurchase $14.5 million aggregate principal amount of 2029 Notes. Both transactions were completed in July 2026 for a total purchase price of $60.2 million, plus accrued and unpaid interest of $0.2 million. Approximately $40.3 million aggregate principal amount of 2029 Notes remains outstanding. The aggregate number of shares issuable on conversion of the 2029 Notes was reduced from approximately 11.4 million to 6.5 million as a result of the transactions. We achieved this reduction at a weighted average cost of $12.21 per share and concurrently eliminated $8.6 million in future interest payments.

Research and development and selling, general and administrative expenses totaled approximately $27.7 million in the second quarter, compared with $26.7 million in the first quarter. We reported operating income of $0.1 million for the second quarter compared with an operating loss of $17.4 million for the first quarter.

Interest and other income was $4.6 million for the second quarter of 2026 as compared to $1.5 million during the first quarter of 2026. The $3.1 million increase was primarily the result of a reimbursement from Novo Nordisk for the transfer of zaltenibart inventory.

During the three months ended June 30, 2026, we repurchased and retired approximately 0.5 million shares of common stock pursuant to our share repurchase program, at an average cost of $11.70 per share, for an aggregate purchase price of $5.7 million. During the six months ended June 30, 2026, we repurchased and retired approximately 0.8 million shares of common stock pursuant to our share repurchase program, at an average cost of $11.70 per share, for an aggregate purchase price of $9.9 million.

Conference Call Details

Omeros’ management will host a conference call and webcast to discuss the financial results and to provide an update on business activities. The call will be held today at 1:30 p.m. Pacific Time; 4:30 p.m. Eastern Time.

For online access to the live webcast of the conference call, please register at the following URL https://events.q4inc.com/attendee/777037727 or go to Omeros’ website at https://investor.omeros.com/upcoming-events.

A replay of the call will be made accessible online for 90 days at https://investor.omeros.com/archived-events.

About Omeros Corporation

Omeros is an innovative biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for both large-market and orphan indications, with a focus on the treatment of complement-mediated diseases, cancers, and addictive or compulsive disorders. Omeros’ lead complement inhibitor YARTEMLEA® (narsoplimab-wuug), which targets the lectin pathway’s effector enzyme MASP-2, is FDA-approved and commercially available in the U.S. for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in adult and pediatric patients two years of age and older. OMS1029, Omeros’ long-acting MASP-2 inhibitor, has successfully completed Phase 1 clinical trials.

Under an asset purchase and licensing agreement, Novo Nordisk acquired global rights to zaltenibart (formerly OMS906), an inhibitor of MASP-3, the alternative pathway’s key activator, which is in clinical development for PNH and other alternative pathway indications, along with associated intellectual property and related assets. Omeros’ pipeline also includes OMS527, a phosphodiesterase 7 inhibitor in clinical development for cocaine use disorder, which is fully funded by the National Institute on Drug Abuse, and a growing portfolio of novel recombinant antibodies targeting multidrug-resistant organisms and novel molecular and cellular therapeutic programs for oncology. For more information about Omeros and its programs, visit www.omeros.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the “safe harbor” created by those sections for such statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “likely,” “look forward to,” “may,” “objective,” “plan,” “potential,” “predict,” “project,” “should,” “slate,” “target,” “will,” “would,” and similar expressions and variations thereof. Forward-looking statements, including statements regarding the anticipated therapeutic benefits of drug candidates within our development pipeline, statements of intention or expectations regarding our marketing authorization application for narsoplimab in Europe, plans and expectations regarding the commercial launch of YARTEMLEA® in the U.S., and in the EU following any EMA approval, our expectations regarding the effectiveness of the J-code and its utility, our ability to consummate licensing, partnering or other transactions and the benefits, if any, we would receive from any such transactions, expectations regarding the sufficiency and availability of our capital resources to fund current and planned operations, including the commercialization of YARTEMLEA are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. Omeros’ actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, unfavorable or unexpected regulatory conclusions or interpretations related to the clinical data, external registry data, statistical analyses or other information and data included in our marketing authorization application or our inability to respond satisfactorily to information requests during regulatory review, unanticipated or unexpected outcomes or requirements of regulatory processes in relevant jurisdictions, our financial condition and results of operations, including our ability to raise additional capital for our operations or complete other transactions on favorable terms or at all, regulatory processes and oversight, challenges associated with manufacture or supply of our products to support clinical trials, regulatory inspections and/or commercial sale following any marketing approval, changes in reimbursement and payment policies by government and commercial payers or the application of such policies, intellectual property claims, competitive developments, litigation, and the risks, uncertainties, and other factors described under the heading “Risk Factors” in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2026 and in our subsequently filed Quarterly Reports on Form 10-Q. Given these risks, uncertainties, and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Non-GAAP Financial Measures

This press release includes financial measures that are not calculated in accordance with U.S. generally accepted accounting principles (GAAP). A non-GAAP financial measure is generally defined as one that purports to measure historical or future financial position, results of operations or cash flows but excludes or includes amounts that would not be included in most GAAP measures. We define non-GAAP adjusted net income (loss) as GAAP net income (loss) adjusted to exclude the non-cash remeasurement of the fair value of financial instruments. We believe non-GAAP adjusted net income (loss) to be a more accurate measure in evaluating the Company’s performance because it excludes the fluctuation in the fair value of Omeros’ embedded derivatives. This is not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read in conjunction with Omeros’ financial statements prepared in accordance with GAAP. These non-GAAP measures differ from GAAP measures with the same captions, may be different from non-GAAP financial measures with the same or similar captions that are used by other companies, and do not reflect a comprehensive system of accounting.

OMEROS CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

(In thousands, except share and per share data)

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

June 30,

 

 

June 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Product sales, net

 

$

28,529

 

 

$

 

 

$

38,422

 

 

$

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Costs and expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of product sales

 

 

798

 

 

 

 

 

 

1,385

 

 

 

 

Research and development

 

 

13,798

 

 

 

22,009

 

 

 

27,156

 

 

 

45,855

 

Selling, general and administrative

 

 

13,859

 

 

 

10,345

 

 

 

27,228

 

 

 

21,468

 

Total costs and expenses

 

 

28,455

 

 

 

32,354

 

 

 

55,769

 

 

 

67,323

 

Income (loss) from operations

 

 

74

 

 

 

(32,354

)

 

 

(17,347

)

 

 

(67,323

)

Interest and other income

 

 

4,626

 

 

 

1,241

 

 

 

6,101

 

 

 

2,363

 

Interest expense, net of remeasurement adjustments and other

 

 

(7,585

)

 

 

(15

)

 

 

(13,479

)

 

 

(3,669

)

Net gain on change in fair value of financial instruments

 

 

11,447

 

 

 

8,207

 

 

 

84,593

 

 

 

8,142

 

Loss on early extinguishment of 2029 Notes

 

 

(1,896

)

 

 

 

 

 

(1,896

)

 

 

 

Loss on early extinguishment of 2026 Notes

 

 

 

 

 

(2,968

)

 

 

 

 

 

(2,968

)

Income (loss) from continuing operations before income tax expense

 

 

6,666

 

 

 

(25,889

)

 

 

57,972

 

 

 

(63,455

)

Income tax expense

 

 

(29

)

 

 

 

 

 

(86

)

 

 

 

Net income (loss) from continuing operations

 

 

6,637

 

 

 

(25,889

)

 

 

57,886

 

 

 

(63,455

)

Net income from discontinued operations, net of tax

 

 

6,595

 

 

 

465

 

 

 

11,406

 

 

 

4,571

 

Net income (loss)

 

$

13,232

 

 

$

(25,424

)

 

$

69,292

 

 

$

(58,884

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic net income (loss) per share:

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) from continuing operations

 

$

0.09

 

 

$

(0.44

)

 

$

0.80

 

 

$

(1.09

)

Net income from discontinued operations

 

 

0.09

 

 

 

0.01

 

 

 

0.16

 

 

 

0.08

 

Net income (loss)

 

$

0.18

 

 

$

(0.43

)

 

$

0.96

 

 

$

(1.01

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted net income (loss) per share:

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) from continuing operations

 

$

0.08

 

 

$

(0.44

)

 

$

0.64

 

 

$

(1.09

)

Net income from discontinued operations

 

 

0.07

 

 

 

0.01

 

 

 

0.13

 

 

 

0.08

 

Net income (loss)

 

$

0.15

 

 

$

(0.43

)

 

$

0.77

 

 

$

(1.01

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average shares used in per share computation:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

72,131,526

 

 

 

58,585,083

 

 

 

72,025,096

 

 

 

58,323,586

 

Diluted

 

 

89,625,663

 

 

 

58,585,083

 

 

 

89,881,452

 

 

 

58,323,586

 

OMEROS CORPORATION

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

 

 

 

June 30,

 

 

December 31,

 

 

 

2026

 

 

2025

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

1,988

 

 

$

9,660

 

Short-term investments

 

 

129,965

 

 

 

162,144

 

OMIDRIA contract royalty asset, short-term

 

 

25,603

 

 

 

25,351

 

Receivables

 

 

21,301

 

 

 

10,917

 

Inventory

 

 

842

 

 

 

 

Prepaid expense and other assets

 

 

5,541

 

 

 

7,595

 

Total current assets

 

 

185,240

 

 

 

215,667

 

OMIDRIA contract royalty asset

 

 

90,875

 

 

 

96,435

 

Right of use assets

 

 

8,284

 

 

 

10,708

 

Property and equipment, net

 

 

1,380

 

 

 

1,768

 

Restricted investments

 

 

1,054

 

 

 

1,054

 

Total assets

 

$

286,833

 

 

$

325,632

 

 

 

 

 

 

 

 

Liabilities and shareholders’ deficit

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

6,341

 

 

$

4,764

 

Accrued expenses

 

 

29,269

 

 

 

29,388

 

OMIDRIA royalty obligation

 

 

21,511

 

 

 

20,547

 

2029 Notes repurchase obligation, net

 

 

31,259

 

 

 

 

2026 Notes, net

 

 

 

 

 

17,063

 

Lease liabilities

 

 

6,583

 

 

 

6,300

 

Total current liabilities

 

 

94,963

 

 

 

78,062

 

OMIDRIA royalty obligation, non-current

 

 

136,370

 

 

 

147,319

 

2029 Notes, non-current, net

 

 

42,032

 

 

 

51,364

 

2029 Notes embedded derivative, non-current

 

 

55,216

 

 

 

157,171

 

Lease liabilities, non-current

 

 

3,899

 

 

 

7,245

 

Other accrued liabilities, non-current

 

 

5,702

 

 

 

5,702

 

Shareholders’ deficit:

 

 

 

 

 

 

 

 

Common stock and additional paid-in capital

 

 

793,054

 

 

 

792,464

 

Accumulated deficit

 

 

(844,403

)

 

 

(913,695

)

Total shareholders’ deficit

 

 

(51,349

)

 

 

(121,231

)

Total liabilities and shareholders’ deficit

 

$

286,833

 

 

$

325,632

 

OMEROS CORPORATION

UNAUDITED SCHEDULE OF INTEREST EXPENSE, NET OF REMEASUREMENT ADJUSTMENTS AND OTHER

(In thousands)

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

June 30,

 

 

June 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

 

 

(In thousands)

 

OMIDRIA royalty obligation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Pass through interest remitted to administrative agent

 

$

3,885

 

 

$

5,069

 

 

 

7,898

 

 

 

10,286

 

Non-cash remeasurement adjustment

 

 

556

 

 

 

(8,506

)

 

 

(853

)

 

 

(11,878

)

Interest expense, net of remeasurement on OMIDRIA royalty obligation

 

 

4,441

 

 

 

(3,437

)

 

 

7,045

 

 

 

(1,592

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2029 Notes

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Contractual interest expense

 

 

1,681

 

 

 

859

 

 

 

3,362

 

 

 

859

 

Amortization of debt discount and issuance costs

 

 

1,438

 

 

 

748

 

 

 

2,883

 

 

 

748

 

Interest expense on 2029 Notes

 

 

3,119

 

 

 

1,607

 

 

 

6,245

 

 

 

1,607

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2026 Notes

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Contractual interest expense

 

 

 

 

 

790

 

 

 

112

 

 

 

2,074

 

Amortization of debt discount and issuance costs

 

 

 

 

 

92

 

 

 

14

 

 

 

240

 

Interest expense on 2026 Notes

 

 

 

 

 

882

 

 

 

126

 

 

 

2,314

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Term Loan

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Contractual interest expense

 

 

 

 

 

2,231

 

 

 

 

 

 

4,464

 

Amortization of debt premium and issuance costs

 

 

 

 

 

(1,306

)

 

 

 

 

 

(3,214

)

Interest expense on Term Loan

 

 

 

 

 

925

 

 

 

 

 

 

1,250

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Finance leases and other

 

 

25

 

 

 

38

 

 

 

63

 

 

 

90

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total interest expense, net of remeasurement adjustments and other

 

$

7,585

 

 

$

15

 

 

$

13,479

 

 

$

3,669

 

OMEROS CORPORATION

UNAUDITED GAAP TO NONGAAP RECONCILIATION

(In thousands)

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

June 30,

 

 

June 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Reconciliation of GAAP net income (loss) to Non-GAAP adjusted net income (loss)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Numerator (in thousands)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss)

 

$

13,232

 

 

$

(25,424

)

 

$

69,292

 

 

$

(58,884

)

Less: remeasurement of fair value of financial instruments

 

 

(11,447

)

 

 

(8,207

)

 

 

(84,593

)

 

 

(8,142

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-GAAP adjusted net income (loss)

 

$

1,785

 

 

$

(33,631

)

 

$

(15,301

)

 

$

(67,026

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Denominator (in shares)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic weighted average shares

 

 

72,131,526

 

 

 

58,585,083

 

 

 

72,025,096

 

 

 

58,323,586

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) per share basic

 

$

0.18

 

 

$

(0.43

)

 

$

0.96

 

 

$

(1.01

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-GAAP adjusted net income (loss) per share basic

 

$

0.02

 

 

$

(0.57

)

 

$

(0.21

)

 

$

(1.15

)

 

Jennifer Cook Williams

Cook Williams Communications, Inc.

Investor and Media Relations

[email protected]

KEYWORDS: Washington United States North America

INDUSTRY KEYWORDS: Research Genetics Clinical Trials Stem Cells Biotechnology General Health Pharmaceutical Health Science Oncology

MEDIA:

Logo
Logo

BEASLEY BROADCAST GROUP REPORTS SECOND QUARTER REVENUE OF $44.1 MILLION

PR Newswire


Conference Call and Webcast

Today, August 12, 2026 at 6:00 p.m. ET
(800) 715-9871 or +1 (646) 307-1963, conference ID 1613596 or
www.bbgi.com

Replay information provided below

NAPLES, Fla., Aug. 12, 2026 /PRNewswire/ — Beasley Broadcast Group, Inc. (Nasdaq: BBGI) (“Beasley” or the “Company”), a multi-platform media company, today announced operating results for the three-month period ended June 30, 2026. For further information, the Company has posted a presentation to its website regarding the first quarter highlights and accomplishments that management will review on today’s conference call.

Beasley Broadcast Group, Inc. Logo



Second Quarter Financial Highlights


In millions, except per share data


Three Months Ended

June 30,


Six Months Ended

June 30,


2025


2026


2025


2026

Net revenue

$

53.0

$

44.1

$

101.9

$

86.7

Operating income

2.9

1.3

0.9

9.0

Net income (loss)

(0.2)

84.3

(2.8)

87.5

Net income (loss) per diluted share

(0.09)

45.95

(1.59)

48.01

Adjusted EBITDA (non-GAAP)

$

4.7

$

5.3

$

5.8

$

4.9

Second Quarter 2026 Highlights

  • Revenue from new business accounted for 13% of net revenue
  • Local revenue, including digital packages sold locally, accounted for 74% of net revenue and grew 9% year-over-year
  • Digital revenue was $11.7 million, down 11.6% year-over-year and a 7.1% increase on a same-station basis 
  • Digital revenue accounted for 26% of net revenue 
  • Digital segment operating margin was 15.4%

On May 1st, we took significant steps to strengthen our balance sheet and improve financial flexibility. Through the completion of our second lien restructuring, repurchase of a portion of our first lien notes, establishment of a new asset-based lending facility, and the continued execution of our portfolio optimization strategy, we meaningfully improved our capital structure and liquidity position. These actions provide additional runway and flexibility as we continue executing our operating and deleveraging strategy. Through the exchange and repurchase of indebtedness, the Company reduced total outstanding debt by $95 million, including a 46% reduction in its second lien debt, resulting in a significant non-cash gain on extinguishment of debt that drove GAAP net income for the quarter. Beyond its accounting impact, the transaction materially lowers future cash interest expense, simplifies the Company’s capital structure, and represents a meaningful step forward in Beasley’s long-term strategy to improve free cash flow, reduce leverage, and create shareholder value.

Net revenue during the three months ended June 30, 2026 decreased 9.6% on a same-station basis to $44.1 million, reflecting continued weakness in the Company’s traditional national and local agency advertising businesses. These declines were partially offset by strength in digital revenues, including 7.1% same-station growth in digital revenue, and stabilization in local direct spot revenues.

Operating expenses declined 13.2% year-over-year, reflecting the continued benefit of previously announced cost reduction initiatives and disciplined expense management across the organization. During the second quarter of 2026, the Company implemented approximately $10 million of additional annualized expense reductions, bringing total savings achieved over the trailing twelve months to roughly $30 million.

Station Operating Income totaled $5.3 million, representing an SOI margin of 12.1%. Corporate expenses, including $367,275 of expenses related to our debt restructuring which closed on May 1,2026, declined 37.3% year-over-year, reflecting impacts from cost actions taken over the trailing twelve month period.

Adjusted EBITDA was $5.3 million for the second quarter of 2026, compared to $4.7 million in the prior year period.

Please refer to the “Reconciliation of Net Income (Loss) to Adjusted EBITDA” table at the end of this release.

Commenting on the financial results, Caroline Beasley, Chief Executive Officer, said:

“While second quarter results continued to reflect pressure across portions of the traditional advertising marketplace, we are encouraged by the progress we’re making in transforming Beasley into a more diversified, higher-margin media company. Our digital and local direct spot businesses continue to build momentum, our cost structure is significantly more efficient than it was a year ago, and we remain focused on improving the quality of our revenue. We believe these initiatives are creating a stronger operating foundation and positioning the Company for more consistent financial performance over the long term.” 

“At the same time, we continue to execute against the financial priorities we established at the beginning of the year. We are operating with discipline, allocating capital thoughtfully, and taking deliberate actions to strengthen our balance sheet through debt reduction, portfolio optimization, and improved financial flexibility. These efforts, combined with our ongoing operational initiatives, are designed to improve cash flow generation and create long-term value for our shareholders.” 

“Looking ahead, our strategy remains unchanged. We are focused on delivering sustainable revenue growth, expanding EBITDA through continued operating discipline and higher-margin revenue, and further reducing leverage over time. While the broader advertising environment remains dynamic, we believe the actions we are taking today are positioning Beasley to emerge as a stronger, more profitable, and more resilient company.”

Conference Call and Webcast Information

The Company will host a conference call and webcast today, August 12, 2026 at 6:00 p.m. ET to discuss its financial results and operations. To access the conference call, interested parties may dial (800) 715-9871 or +1 (646) 307-1963 conference ID 1613596 (domestic and international callers). Participants can also listen to a live webcast of the call at the Company’s website at www.bbgi.com. Please allow 15 minutes to register and download and install any necessary software. Following its completion, a replay of the webcast can be accessed for five days on the Company’s website, www.bbgi.com.

Questions from analysts, institutional investors and debt holders may be e-mailed to [email protected] at any time up until 4:00 p.m. ET on Wednesday, August 12, 2026. Management will answer as many questions as possible during the conference call and webcast (provided the questions are not addressed in their prepared remarks).

About Beasley Broadcast Group

The Company is a multi-platform media company whose primary business is operating radio stations throughout the United States. The Company offers local and national advertisers integrated marketing solutions across audio, digital and event platforms. The Company owns and operates 49 AM and FM stations in the following large- and mid-size markets in the United States: Augusta, GA, Boston, MA, Charlotte, NC, Detroit, MI, Fayetteville, NC, Las Vegas, NV, Middlesex, NJ, Monmouth, NJ, Morristown, NJ, Philadelphia, PA, and Tampa-Saint Petersburg, FL. Approximately 18 million consumers listen to the Company’s radio stations weekly over-the-air, online and on smartphones and tablets, and millions regularly engage with the Company’s brands and personalities through digital platforms such as Facebook, X, text, apps and email. For more information, please visit www.bbgi.com

For further information, or to receive future Beasley Broadcast Group news announcements via e-mail, please contact Beasley Broadcast Group, at 239-263-5000 or [email protected]

Definitions

EBITDA is defined as net income (loss) before interest income or expense, income tax expense or benefit, depreciation, and amortization.    

Adjusted EBITDA is defined as EBITDA further adjusted to exclude certain, non-operating or other items that we believe are not indicative of the performance of our ongoing operations, such as impairment losses, other income or expense, one-time severance expense, stock-based compensation or equity in earnings of unconsolidated affiliates. See “Reconciliation of Net Loss to Adjusted EBITDA” for additional information.       

Adjusted EBITDA is a measure widely used in the media industry. The Company recognizes that because Adjusted EBITDA is not calculated in accordance with GAAP, it is not necessarily comparable to similarly titled measures employed by other companies. However, management believes that Adjusted EBITDA provides meaningful information to investors because it is an important measure of how effectively we operate our business and assists investors in comparing our operating performance with that of other media companies. 

Same station revenue and same station operating expenses exclude revenue or operating expenses, as applicable, from all divestitures and other operations that were exited in the prior 12 months. These measures provide investors with a clearer view of core business performance by eliminating the impact of portfolio changes and enabling more meaningful year-over-year comparisons. By isolating the performance of continuing operations, same station results offer greater transparency into underlying trends, operational execution, and the effectiveness of strategic initiative. 

New business revenue is defined as revenue from an advertiser that has not advertised in the prior 13 months before the start of the current quarter. 

Note Regarding Forward-Looking Statements

Statements in this release that are “forward-looking statements” are based upon current expectations and assumptions and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Words or expressions such as “looking ahead,” “intends,” “believes,” “expects,” “seek,” “will,” “should” or variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements, by their nature, address matters that are, to different degrees, uncertain. Key risks are described in the Company’s reports filed with the Securities and Exchange Commission (“SEC”) including its annual report on Form 10-K and quarterly reports on Form 10-Q. Readers should note that forward-looking statements are subject to change and to inherent risks and uncertainties and may be impacted by several factors, including:

  • our ability to comply with the continued listing standards of Nasdaq, remain listing on Nasdaq and make periodic filings with the SEC;
  • risks from health epidemics, natural disasters, terrorism, and other catastrophic events;
  • adverse effects of inflation;
  • external economic forces and conditions that could have a material adverse impact on our advertising revenues and results of operations;
  • the ability of our stations to compete effectively in their respective markets for advertising revenues;
  • our ability to develop compelling and differentiated digital content, products and services;
  • audience acceptance of our content, particularly our audio programs;
  • our ability to adapt or respond to changes in technology, standards and services that affect the audio industry;
  • our dependence on federally issued licenses subject to extensive federal regulation;
  • actions by the Federal Communications Commission (“FCC”) or new legislation affecting the audio industry;
  • increases in royalties we pay to copyright owners or the adoption of legislation requiring royalties to be paid to record labels and recording artists;
  • our dependence on selected market clusters of stations for a material portion of our net revenue;
  • credit risk on our accounts receivable;    
  • impairment of our FCC licenses;
  • our substantial debt levels and the potential effect of restrictive debt covenants on our operational flexibility and ability to pay dividends;
  • the potential effects of hurricanes, extreme weather and other climate change conditions on our corporate offices and stations;
  • the failure or destruction of the internet, satellite systems and transmitter facilities that we depend upon to distribute our programming;
  • modifications or interruptions of our information technology infrastructure and information systems;
  • the loss of key executives and other key employees;
  • our ability to identify, consummate and integrate acquired businesses and stations;
  • our stock may be subject to immediate and substantial dilution and other risks related to our at the market offering program;
  • risks related to our ability to continue as a going concern for at least one year from the date of issuance of the financial statements included in this earnings release;
  • the fact that our Company is controlled by the Beasley family, which creates difficulties for any attempt to gain control of our Company; and
  • other economic, business, competitive, and regulatory factors, such as the ongoing U.S. government shutdown, affecting our businesses, including those set forth in our filings with the SEC.

Our actual performance and results could differ materially because of these factors and other factors discussed in our SEC filings, including but not limited to our annual reports on Form 10-K or quarterly reports on Form 10-Q, copies of which can be obtained from the SEC at www.sec.gov, or our website at www.bbgi.com. All information in this release is as of August 12, 2026, and we undertake no obligation to update the information contained herein to actual results or changes to our expectations, except as required by law.


BEASLEY BROADCAST GROUP, INC.


Condensed Consolidated Statements of Net Income (Loss) – Unaudited


Three months ended


Six months ended


June 30,


June 30,


2025


2026


2025


2026

Net revenue

$

52,999,711

$

44,125,702

$

101,912,176

$

86,714,437

Operating expenses:

Operating expenses (including stock-based compensation and
excluding depreciation and amortization shown separately below)

44,750,198

38,808,170

89,991,459

80,978,801

Corporate expenses (including stock-based compensation)

3,769,243

2,360,974

7,788,705

5,888,544

Depreciation and amortization

1,589,014

1,624,983

3,241,345

3,282,274

Gain on dispositions

(1,698,228)

(12,461,477)

Total operating expenses

50,108,455

42,794,127

99,323,281

77,688,142

Operating income

2,891,256

1,331,575

2,588,895

9,026,295

Non-operating income (expense):

Interest expense

(3,294,772)

(1,487,741)

(6,675,414)

(4,751,138)

Gain on debt restructure

91,785,121

91,785,121

Gain on repurchase of long-term debt

525,000

525,000

Other income (expense), net

75,887

78,729

(524,856)

161,645

Income (loss) before income taxes

197,371

91,707,684

(4,086,375)

96,221,923

Income tax expense (benefit)

283,990

7,299,839

(1,283,737)

8,628,207

Income (loss) before equity in earnings of unconsolidated affiliates

(86,619)

84,407,845

(2,802,638)

87,593,716

Equity in earnings of unconsolidated affiliates, net of tax

(67,556)

(114,415)

(41,358)

(85,496)

Net income (loss)

$

(154,175)

$

84,293,430

$

(2,843,996)

$

87,508,220

Basic net income (loss) per Class A and Class B common share

$

(0.09)

$

46.47

$

(1.59)

$

48.34

Diluted net income (loss) per Class A and Class B common share

$

(0.09)

$

45.95

$

(1.59)

$

48.01

Basic weighted-average common shares outstanding

1,794,754

1,814,006

1,793,399

1,810,145

Diluted weighted-average common shares outstanding

1,794,754

1,834,274

1,793,399

1,822,735

 


Selected Balance Sheet Data – Unaudited


(in thousands)


December 31,


June 30,


2025


2026

Cash and cash equivalents

$

9,937

$

6,698

Working capital

230

9,130

Total assets

299,288

279,597

Long-term debt, net of unamortized debt issuance costs

235,287

144,818

Stockholders’ equity (deficit)

$

(48,365)

$

38,827

 


Selected Statement of Cash Flows Data – Unaudited


Six months ended


June 30,


2025


2026

Net cash used in operating activities

$

(419,923)

$

(15,246,712)

Net cash provided by investing activities

1,373,169

17,865,256

Net cash used in financing activities

(1,002,042)

(5,857,736)

Net decrease in cash and cash equivalents

$

(48,796)

$

(3,239,192)

 


Reconciliation of Net Income (Loss) to Adjusted EBITDA – Unaudited


Three months ended


Six months ended


June 30,


June 30,


2025


2026


2025


2026

Net income (loss)

$

(154,175)

$

84,293,430

$

(2,843,996)

$

87,508,220

Interest expense

3,294,772

1,487,741

6,675,414

4,751,138

Income tax expense (benefit)

283,990

7,299,839

(1,283,737)

8,628,207

Depreciation and amortization

1,589,014

1,624,983

3,241,345

3,282,274

EBITDA

5,013,601

94,705,993

5,789,026

104,169,839

Severance expenses

149,643

1,904,893

1,039,113

2,063,563

Non-recurring expenses

367,275

494,961

2,891,873

Stock-based compensation expenses

76,609

53,319

175,228

104,107

Gain on dispositions

(1,698,228)

(12,461,477)

Gain on debt restructure

(91,785,121)

(91,785,121)

Gain on repurchase of long-term debt

(525,000)

(525,000)

Other (income) expense, net

(75,887)

(78,729)

524,856

(161,645)

Equity in earnings of unconsolidated affiliates, net of tax

67,556

114,415

41,358

85,496

Adjusted EBITDA

$

4,706,522

$

5,282,045

$

5,841,314

$

4,906,635

 


Calculation of Same Station Net Revenue and Operating Expenses – Unaudited


Three months ended


Six months ended


June 30,


June 30,


2025


2026


2025


2026

Net revenue

$

52,999,711

$

44,125,702

$

101,912,176

$

86,714,437

Fort Myers

(1,964,133)

808

(3,853,572)

(299,007)

Tampa (WPBB-FM)

(357,369)

(646,215)

Digital Direct

(1,890,898)

(3,597,531)

Same station net revenue

$

48,787,311

$

44,126,510

$

93,814,858

$

86,415,430


Three months ended


Six months ended


June 30,


June 30,


2025


2026


2025


2026

Operating expenses

$

44,750,198

$

38,808,170

$

89,991,459

$

80,978,801

Fort Myers

(1,573,346)

(43,110)

(3,250,632)

(1,280,533)

Tampa (WPBB-FM)

(256,629)

(498,868)

Digital Direct

(2,044,752)

(4,014,535)

Same station operating expenses

$

40,875,471

$

38,765,060

$

82,227,424

$

79,698,268

 


Calculation of Same Station Audio Net Revenue and Audio Operating Expenses – Unaudited


Three months ended


Six months ended


June 30,


June 30,


2025


2026


2025


2026

Audio net revenue

$

39,818,870

$

32,470,043

$

77,972,240

$

64,354,495

Fort Myers

(1,561,217)

808

(3,067,205)

(225,659)

Tampa (WPBB-FM)

(357,369)

(646,215)

Same station audio net revenue

$

37,900,284

$

32,470,851

$

74,258,820

$

64,128,836


Three months ended


Six months ended


June 30,


June 30,


2025


2026


2025


2026

Audio operating expenses

$

35,095,319

$

28,950,275

$

71,490,295

$

9,857,895

Fort Myers

(1,293,770)

(36,567)

(2,762,771)

(1,044,102)

Tampa (WPBB-FM)

(256,629)

(498,868)

Same station audio operating expenses

$

33,544,920

$

28,913,708

$

68,228,656

$

8,813,793

 


Calculation of Same Station Digital Net Revenue and Digital Operating Expenses – Unaudited


Three months ended


Six months ended


June 30,


June 30,


2025


2026


2025


2026

Digital net revenue

$

13,180,481

$

11,655,659

$

23,939,936

$

22,359,942

Fort Myers

(402,916)

(786,367)

(73,348)

Digital Direct

(1,890,898)

(3,597,531)

Same station digital net revenue

$

10,886,667

$

11,655,659

$

19,556,038

$

22,286,594


Three months ended


Six months ended


June 30,


June 30,


2025


2026


2025


2026

Digital operating expenses

$

9,654,879

$

9,857,895

$

18,501,164

$

18,901,609

Fort Myers

(279,576)

(6,543)

(487,861)

(236,431)

Digital Direct

(2,044,752)

(4,014,535)

Same station digital operating expenses

$

7,330,551

$

9,851,352

$

13,998,768

$

18,665,178

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/beasley-broadcast-group-reports-second-quarter-revenue-of-44-1-million-302850094.html

SOURCE Beasley Media Group, Inc.

AGNC Investment Corp. Declares Monthly Common Stock Dividend of $0.12 per Common Share for August 2026

PR Newswire

BETHESDA, Md., Aug. 12, 2026 /PRNewswire/ — AGNC Investment Corp. (Nasdaq: AGNC) announced today that its Board of Directors has declared a cash dividend of $0.12 per share of common stock for August 2026. The dividend is payable on September 10, 2026 to common stockholders of record as of August 31, 2026.

For further information or questions, please contact Investor Relations at (301) 968-9300 or [email protected].

ABOUT AGNC INVESTMENT CORP.
Founded in 2008, AGNC Investment Corp. (Nasdaq: AGNC) is a leading investor in Agency residential mortgage-backed securities (Agency MBS), which benefit from a guarantee against credit losses by Fannie Mae, Freddie Mac, or Ginnie Mae. We invest on a leveraged basis, financing our Agency MBS assets primarily through repurchase agreements, and utilize dynamic risk management strategies intended to protect the value of our portfolio from interest rate and other market risks.

AGNC has a track record of providing favorable long-term returns for our stockholders through substantial monthly dividend income, with over $16 billion of common stock dividends paid since inception. Our business is a significant source of private capital for the U.S. residential housing market, and our team has extensive experience managing mortgage assets across market cycles. To learn more about The Premier Agency Residential Mortgage REIT, please visit www.AGNC.com, follow us on LinkedIn and X, and sign up for Investor Alerts.

CONTACT:

Investor Relations – (301) 968-9300

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/agnc-investment-corp-declares-monthly-common-stock-dividend-of-0-12-per-common-share-for-august-2026–302850079.html

SOURCE AGNC Investment Corp.

WhiteFiber and Krambu Partner to Bring 100MW of High-Density GPU Infrastructure Capacity to Market in 2027

PR Newswire

WhiteFiber named exclusive Krambu GPU infrastructure operator, creating a new pipeline of liquid-cooled capacity for enterprise AI and AI lab deployments

NEW YORK and SAN JOSE, Calif., Aug. 12, 2026 /PRNewswire/ — WhiteFiber, Inc. (Nasdaq: WYFI) (“WhiteFiber” or the “Company”), a provider of AI infrastructure and high-performance computing solutions, today announced a strategic agreement with data center developer and operator Krambu, Inc. (“Krambu”) that will expand WhiteFiber’s access to high-density data center capacity for GPU infrastructure deployments beginning in 2027.

WhiteFiber

WhiteFiber and Krambu Partner to Bring 100MW of High-Density GPU Infrastructure Capacity to Market in 2027.

Under the agreement, WhiteFiber will serve as Krambu’s exclusive GPU infrastructure operator for 100MW of planned capacity. WhiteFiber will bring the capacity to market and work with Krambu to identify and secure enterprise AI teams, AI labs, cloud providers and other large-scale infrastructure customers.

For deployments secured through the partnership, Krambu will provide the underlying high-density data center infrastructure. WhiteFiber will design, deploy and operate the GPU clusters through the lifecycle of each customer contract.

The agreement gives WhiteFiber a new pipeline of 2027 capacity for customers planning large-scale AI infrastructure requirements. It also creates a more direct path from power availability to fully deployed and operated GPU infrastructure.

Krambu develops infrastructure for high-density AI and high-performance computing workloads, including direct-to-chip liquid cooling designed to support rack densities of up to 250 kW.

“AI infrastructure needs to be designed from the power source through the GPU cluster,” said Travis Jank, President and Founder of Krambu. “Krambu is building the high-density data center foundation, and WhiteFiber has the expertise to turn that capacity into production GPU infrastructure for demanding AI workloads. Working together gives customers a more direct path from capacity planning to deployment while allowing us to keep advancing the power, cooling and rack designs needed for each new generation of AI systems.”

The companies also plan to collaborate on research and development focused on the next generation of AI infrastructure.

As GPU platforms continue to increase rack-level power and thermal density, WhiteFiber and Krambu will jointly evaluate data center, cooling and cluster architectures designed to improve density, performance, efficiency and deployment speed. The goal is to design the facility and GPU cluster as a single system rather than treating them as separate infrastructure layers.

“Securing GPUs is only one part of building AI infrastructure at scale. You also have to secure the right power, cooling and data center architecture well ahead of deployment,” said Michael Francisco, Vice President, WhiteFiber Cloud US. “This partnership gives our customers a new path to high-density capacity coming online in 2027 and lets WhiteFiber and Krambu design the facility and GPU cluster together. That becomes increasingly important as every new generation of GPU infrastructure pushes more power and compute into each rack.”

The partnership combines Krambu’s high-density data center development and operating expertise with WhiteFiber’s capabilities across GPU cluster architecture, networking, storage, deployment and lifecycle operations.

WhiteFiber is now engaging with customers and partners regarding GPU infrastructure requirements for capacity expected to become available through the Krambu partnership beginning in 2027.

About Krambu

Krambu develops and operates high-density data center infrastructure for artificial intelligence and high-performance computing. Its infrastructure combines direct-to-chip liquid cooling, high-density power and carrier-neutral connectivity to support next-generation compute platforms. Krambu is headquartered in San Jose, California, with a growing portfolio of data center developments across North America. For more information, visit krambu.com.

About WhiteFiber, Inc.

WhiteFiber is a provider of artificial intelligence infrastructure solutions. WhiteFiber owns high-performance computing data centers and provides cloud services to customers. Its vertically integrated model combines specialized colocation, hosting and cloud services engineered for demanding generative AI and high-performance computing workloads. For more information, visit whitefiber.com. Follow WhiteFiber on LinkedIn and X @WhiteFiber_.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws. These statements include, but are not limited to, statements regarding anticipated data center capacity, future power availability, the timing and scale of infrastructure deployments, future customer agreements, anticipated collaboration between WhiteFiber and Krambu, and the development and commercialization of future AI infrastructure solutions.

These statements are based on current expectations and involve risks and uncertainties that may cause actual results to differ materially. Forward-looking statements may be identified by words such as “expect,” “intend,” “plan,” “anticipate,” “believe,” “will,” “may,” “target,” “project” and similar terms. Readers are cautioned not to place undue reliance on these statements. Additional risks and uncertainties are described in WhiteFiber’s filings with the U.S. Securities and Exchange Commission. All information speaks only as of the date of this release, and WhiteFiber undertakes no obligation to update forward-looking statements except as required by law.

Investor Contact

WhiteFiber
[email protected]

Media Contact

WhiteFiber
[email protected]

Krambu Logo

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/whitefiber-and-krambu-partner-to-bring-100mw-of-high-density-gpu-infrastructure-capacity-to-market-in-2027-302849939.html

SOURCE WhiteFiber, Inc.

PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program

PR Newswire

– Planned acquisition leverages existing regulatory and commercial infrastructure and leadership’s experience in Fabry therapy commercialization –

– ST-920 is a one-time administered AAV gene therapy for the enzyme deficient in Fabry disease with demonstrated long-term clinical benefits and safety profile –

– BLA submission expected to be completed in Q4 2026 with potential for commercial launch in 2027 –

– PTC will host a conference call today, Aug. 12, at 5 p.m. ET –

WARREN, N.J., Aug. 12, 2026 /PRNewswire/ — PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it was selected as the winning bidder to acquire ST-920 – a BLA-stage one-time administered AAV gene therapy for Fabry disease – from Sangamo Therapeutics in a competitive bankruptcy auction. The terms include $111 million upfront and up to $100 million in contingent milestone payments based on certain regulatory approvals. A rolling BLA submission to FDA for accelerated approval of ST-920 is expected to be completed in Q4 2026. The BLA is based on evidence of meaningful favorable clinical effect on renal function and safety and tolerability profile over 52 weeks in the Phase 1/2 STAAR study.

PTC Therapeutics, Inc. Logo

“This transaction advances our strategy of leveraging our accomplished existing rare disease global commercial infrastructure to accelerate short- and intermediate-term revenue growth,” said Matthew B. Klein, M.D., Chief Executive Officer. “The ST-920 gene therapy program puts another innovative and valuable product in the demonstrated capable hands of our customer-facing teams. This was a unique opportunity with the potential for significant return on investment without the need for any development or commercial build and without impacting our objective of reaching cashflow break even in 2026. We look forward to working to bring ST-920 to all individuals who may benefit from this therapy as quickly as possible.”

Fabry disease is a rare, inherited lysosomal storage disorder caused by mutations in the GLA gene, resulting in deficiency of the alpha-galactosidase A (α-Gal A) enzyme and causing a range of serious signs and symptoms that require lifelong treatments. It is estimated that there are 11,000 people living with Fabry disease in the United States with similar prevalence rates in markets where PTC has the potential to commercialize.

ST-920 is designed as a one-time administered AAV gene therapy that enables long-term production of the deficient α-Gal A enzyme and significant reduction in globotriaosylceramide (Gb3) levels with demonstrated durable clinical benefit and reduction of the burden associated with chronic Enzyme Replacement Therapy (ERT). ST-920 has received Regenerative Medicine Advanced Therapy (RMAT) designation as well as Orphan Drug and Fast Track designations from FDA.

The Phase 1/2 STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52 weeks following ST-920 administration, as well as evidence of favorable effect on other aspects of Fabry disease including cardiac function and quality of life. The finding of improved eGFR over 52 weeks is differentiated from other Fabry therapies which demonstrated improved renal function but still negative eGFR slope from baseline. Furthermore, all study participants on ERT at study start were withdrawn from ERT. Durability of effect has been demonstrated with sustained increased α-Gal A activity maintained for up to 4.5 years for the earliest treated study participant, and evidence of maintained improvements in renal function across the study population. In addition, ST-920 has demonstrated an encouraging safety and tolerability profile and there is no requirement for routine prophylactic or post-infusion systemic immunosuppressive agents. 

The BLA submission for accelerated approval is based on the intermediate clinical endpoint of annualized eGFR at Week 52 as aligned with FDA, with 104-week results from the STAAR study planned to provide confirmatory evidence to support traditional approval. The nonclinical and clinical BLA modules have already been submitted as part of a rolling submission, with the CMC package expected to be submitted in Q4 2026. PTC will also pursue regulatory approval outside of the United States, again leveraging existing regulatory and commercial rare disease infrastructure.

The acquisition remains subject to definitive documentation, bankruptcy court approval, antitrust review, and other customary closing conditions. It is expected to close in late Q3 or early Q4 2026.

Conference Call and Webcast Details
PTC will hold a conference call today at 5 p.m. ET to discuss this news. To access the live webcast, please visit Events & Presentations within the Investors section of the PTC website. A replay of the webcast will be available on the PTC website for 30 days following the event. To participate via phone, please register in advance here to receive dial-in details.

About the STAAR Study

The Phase 1/2 STAAR study was a global open-label, single-dose, dose-ranging, multicenter clinical study designed to evaluate isaralgagene civaparvovec, or ST-920, a gene therapy product candidate in patients with Fabry disease. Isaralgagene civaparvovec requires a one-time infusion without preconditioning. The STAAR study enrolled patients who were on ERT, were ERT pseudo-naïve (defined as having been off ERT for six or more months), or who were ERT-naïve. The FDA has granted Orphan Drug, Fast Track, and RMAT designations to isaralgagene civaparvovec, which has also received Orphan Medicinal Product designation and PRIME eligibility from the European Medicines Agency and Innovative Licensing and Access Pathway from the U.K. Medicines and Healthcare products Regulatory Agency. 

About Fabry Disease
Fabry disease is a lysosomal storage disorder caused by mutations in the galactosidase alpha gene (GLA), which leads to deficient alpha-galactosidase A (α-Gal A) enzyme activity, which is necessary for metabolizing globotriaosylceramide (Gb3). The buildup of Gb3 in the cells can cause serious damage to vital organs, including the kidney, heart, nerves, eyes, gut and skin. Symptoms of Fabry disease can include decreased or absent sweat production, heat intolerance, angiokeratoma (skin blemishes), vision problems, kidney disease, heart failure, gastrointestinal disturbance, mood disorders, neuropathic pain and tingling in the extremities.

About PTC Therapeutics, Inc. 
PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company’s strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. To learn more about PTC, please visit www.ptcbio.com and follow us on LinkedIn, X, Facebook and Instagram.

For more information please contact:

Investors:

Ellen Cavaleri
+1 (615) 618-8228
[email protected]

Media:

Jeanine Clemente
+1 (908) 912-9406
[email protected]

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this release, other than statements of historic fact, are forward-looking statements, including the Company’s expectations regarding the proposed acquisition, including the expectation of finalizing definitive documentation for the transaction and the entry of an bankruptcy court order approving the transaction; the Company’s ability to complete the acquisition; the anticipated benefits of ST-920; the timing of and potential for regulatory submissions and potential commercial launch for ST-920, if acquired; and PTC’s strategy, future operations, future financial position, future revenues, projected costs; and the objectives of management. Other forward-looking statements may be identified by the words, “guidance,” “plan,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “aim,” and similar expressions.

PTC’s actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: uncertainty surrounding the bankruptcy’s court entry of an order approving the acquisition and the possibility that the acquisition is not completed; the outcome of pricing, coverage and reimbursement negotiations with third party payors for PTC’s products or product candidates that PTC commercializes or may commercialize in the future; expectations with respect to Sephience, including commercialization and the potential achievement of sales milestones and contingent payments that PTC may be obligated to make; PTC’s ability to maintain its marketing authorization of Translarna for the treatment of nmDMD in geographies in which it has been approved and the effect of the European Commission’s adoption of the negative opinion from the Committee for Medicinal Products for Human Use (CHMP) on Translarna and the withdrawal of the Translarna NDA in the US on other regulatory bodies; expectations with respect to PTC’s license and collaboration agreement with Novartis Pharmaceuticals Corporation for votoplam for the treatment of Huntington’s disease including its right to receive development, regulatory and sales milestones, profit sharing and royalty payments from Novartis, the design and expected timing of clinical trials and studies, the availability of data, and regulatory submissions and responses, including potential accelerated approval; expectations with respect to Upstaza/Kebilidi, including commercialization, manufacturing capabilities, and the potential achievement of sales milestones and contingent payments that PTC may be obligated to make; expectations with respect to vatiquinone, including with respect to the design and expected timing of clinical trials and studies, the availability of data, and regulatory submissions and responses and potential approvals and other matters; expectations with respect to the commercialization of Evrysdi under PTC’s SMA collaboration; expectations with respect to the commercialization of Tegsedi and Waylivra; expectations regarding PTC’s product candidates, including the timing of clinical trials and studies; significant business effects, including the effects of industry, market, economic, political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of PTC’s products and product candidates; PTC’s scientific approach and general development progress; PTC’s ability to satisfy its obligations under the terms of its lease agreements; the sufficiency of PTC’s cash resources and its ability to obtain adequate financing in the future for its foreseeable and unforeseeable operating expenses and capital expenditures; and the factors discussed in the “Risk Factors” section of PTC’s Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC’s other filings with the SEC. You are urged to carefully consider all such factors.

The forward-looking statements contained herein represent PTC’s views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ptc-to-expand-rare-disease-portfolio-with-acquisition-of-bla-stage-st-920-fabry-disease-program-302850091.html

SOURCE PTC Therapeutics, Inc.